1
|
Ramachandran D, Tyrer JP, Kommoss S, DeFazio A, Riggan MJ, Webb PM, Fasching PA, Lambrechts D, García MJ, Rodríguez-Antona C, Goodman MT, Modugno F, Moysich KB, Karlan BY, Lester J, Kjaer SK, Jensen A, Høgdall E, Goode EL, Cliby WA, Kumar A, Wang C, Cunningham JM, Winham SJ, Monteiro AN, Schildkraut JM, Cramer DW, Terry KL, Titus L, Bjorge L, Thomsen LCV, Pejovic T, Høgdall CK, McNeish IA, May T, Huntsman DG, Pfisterer J, Canzler U, Park-Simon TW, Schröder W, Belau A, Hanker L, Harter P, Sehouli J, Kimmig R, de Gregorio N, Schmalfeldt B, Baumann K, Hilpert F, Burges A, Winterhoff B, Schürmann P, Speith LM, Hillemanns P, Berchuck A, Johnatty SE, Ramus SJ, Chenevix-Trench G, Pharoah PDP, Dörk T, Heitz F. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease. NPJ Genom Med 2024; 9:19. [PMID: 38443389 PMCID: PMC10915171 DOI: 10.1038/s41525-024-00395-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 01/15/2024] [Indexed: 03/07/2024] Open
Abstract
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous carcinoma (HGSOC), to identify variants associated with residual disease. The most significant association with resection status was observed for rs72845444, upstream of MGMT, in HGSOC (p = 3.9 × 10-8). In gene-based analyses, PPP2R5C was the most strongly associated gene in HGSOC after stage adjustment. In an independent set of 378 ovarian tumours from the AGO-OVAR 11 study, variants near MGMT and PPP2R5C correlated with methylation and transcript levels, and PPP2R5C mRNA levels predicted progression-free survival in patients with residual disease. MGMT encodes a DNA repair enzyme, and PPP2R5C encodes the B56γ subunit of the PP2A tumour suppressor. Our results link heritable variation at these two loci with resection status in HGSOC.
Collapse
Grants
- K05 CA154337 NCI NIH HHS
- R01 CA058598 NCI NIH HHS
- UL1 TR000124 NCATS NIH HHS
- P50 CA105009 NCI NIH HHS
- K07 CA080668 NCI NIH HHS
- P30 CA076292 NCI NIH HHS
- R01 CA076016 NCI NIH HHS
- R01 CA248288 NCI NIH HHS
- U19 CA148112 NCI NIH HHS
- R01 CA149429 NCI NIH HHS
- Wellcome Trust
- P50 CA136393 NCI NIH HHS
- R21 CA267050 NCI NIH HHS
- M01 RR000056 NCRR NIH HHS
- R01 CA095023 NCI NIH HHS
- R01 CA054419 NCI NIH HHS
- P30 CA015083 NCI NIH HHS
- Deutsche Forschungsgemeinschaft (German Research Foundation)
- The Ovarian Cancer Association Consortium is funded by generous contributions from its research investigators and through anonymous donations. OCAC was funded by a grant from the Ovarian Cancer Research Fund (OCRF). The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of Health (CA1X01HG007491-01 (C.I.A.), U19-CA148112 (T.A.S.), R01-CA149429 (C.M.P.) and R01-CA058598 (M.T.G.); Canadian Institutes of Health Research (MOP-86727 (L.E.K.) and the Ovarian Cancer Research Fund (A.B.). The COGS project was funded through a European Commission’s Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175) and in part by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113. The results published are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). Funding for individual studies: AUS: The Australian Ovarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). AOCS gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: ELAN Funds of the University of Erlangen-Nuremberg; BEL: National Kankerplan; CNI: Instituto de Salud Carlos III (PI 19/01730); Ministerio de Economía y Competitividad (SAF2012); HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: University of Pittsburgh School of Medicine Dean’s Faculty Advancement Award (F. Modugno), Department of Defense (DAMD17-02-1-0669, OC20085) and United States National Cancer Institute (R21-CA267050, K07-CA080668, R01-CA95023, MO1-RR000056); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; MAC: National Institutes of Health (R01-CA2482288, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; MAL: Funding for this study was provided by research grant R01- CA61107 from the National Cancer Institute, Bethesda, MD, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark, the Mermaid I project; and the Mermaid III project; MAY: National Institutes of Health (R01-CA2482288, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MOF: Moffitt Cancer Center, Merck Pharmaceuticals, the state of Florida, Hillsborough County, and the city of Tampa; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NOR: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway; OPL: National Health and Medical Research Council (NHMRC) of Australia (APP1025142, APP1120431) and Brisbane Women’s Club; ORE: Sherie Hildreth Ovarian Cancer (SHOC) Foundation; PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program; SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589); UHN: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; VAN: BC Cancer Foundation, VGH & UBC Hospital Foundation; VTL: NIH K05-CA154337; WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 & ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16. The AGO-OVAR 11 study was funded by Roche Pharma AG.
- National Health and Medical Research Council (NHMRC) of Australia (APP1025142, APP1120431) and Brisbane Women’s Club
Collapse
Affiliation(s)
| | - Jonathan P Tyrer
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Stefan Kommoss
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - Anna DeFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia
- Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, NSW, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Marjorie J Riggan
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA
| | - Penelope M Webb
- Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Peter A Fasching
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
- VIB Center for Cancer Biology, VIB, Leuven, Belgium
| | - María J García
- Biochemistry and Molecular Biology area, Department of Basic Health Sciences, Faculty of Health Sciences, Rey Juan Carlos University, Madrid, Spain
| | - Cristina Rodríguez-Antona
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Marc T Goodman
- Cancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Francesmary Modugno
- Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA
| | - Kirsten B Moysich
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - Beth Y Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA
| | - Jenny Lester
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen, Denmark
| | - Estrid Høgdall
- Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Ellen L Goode
- Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - William A Cliby
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA
| | - Amanika Kumar
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA
| | - Chen Wang
- Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA
| | - Julie M Cunningham
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Stacey J Winham
- Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA
| | - Alvaro N Monteiro
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Joellen M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Daniel W Cramer
- Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gyneclogy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Kathryn L Terry
- Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gyneclogy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Linda Titus
- Norris Cotton Cancer Center, Lebanon, NH, USA
| | - Line Bjorge
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Liv Cecilie Vestrheim Thomsen
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Tanja Pejovic
- Department of ObGyn, Providence Medical Center, Medford, OR, USA
- Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
| | - Claus K Høgdall
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Iain A McNeish
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Taymaa May
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
| | - David G Huntsman
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
| | | | - Ulrich Canzler
- University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
| | | | - Willibald Schröder
- Klinikum Bremen-Mitte, Bremen, Germany
- Gynaekologicum Bremen, Bremen, Germany
| | - Antje Belau
- University Hospital Greifswald, Greifswald, Germany
- Frauenarztpraxis Belau, Greifswald, Germany
| | - Lars Hanker
- University Hospital Frankfurt, Frankfurt, Germany
- University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
| | - Philipp Harter
- Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany
| | - Jalid Sehouli
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
| | - Rainer Kimmig
- University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Nikolaus de Gregorio
- University Hospital Ulm, Ulm, Germany
- SLK-Kliniken Heilbronn, Klinikum am Gesundbrunnen, Heilbronn, Germany
| | | | - Klaus Baumann
- University Hospital Gießen and Marburg, Site Marburg, Marburg, Germany
- Klinikum Ludwigshafen, Ludwigshafen, Germany
| | - Felix Hilpert
- University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
- Krankenhaus Jerusalem, Mammazentrum Hamburg, Hamburg, Germany
| | | | - Boris Winterhoff
- Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
| | - Peter Schürmann
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Lisa-Marie Speith
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Peter Hillemanns
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Andrew Berchuck
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA
| | - Sharon E Johnatty
- Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Susan J Ramus
- School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, NSW, Australia
| | | | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
- Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Thilo Dörk
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
| | - Florian Heitz
- Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany.
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
- Department of Gynecology and Gynecological Oncology, HSK, Dr. Horst-Schmidt Klinik, Wiesbaden, Wiesbaden, Germany.
| |
Collapse
|
2
|
Kristensen AK, Frandsen CLB, Nøhr B, Viuff JH, Hargreave M, Frederiksen K, Kjær SK, Jensen A. Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women. Gynecol Oncol 2024; 185:108-115. [PMID: 38382167 DOI: 10.1016/j.ygyno.2024.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/29/2024] [Accepted: 02/08/2024] [Indexed: 02/23/2024]
Abstract
OBJECTIVE Results from previous studies examining the association between fertility treatment and borderline ovarian tumors are inconsistent. The aim of this study was to investigate the association between fertility treatment and borderline ovarian tumors in a cohort of infertile women. METHODS This cohort study was based on the Danish Infertility Cohort and included all infertile women aged 20-45 years living in Denmark between 1 January 1995 and 31 December 2017 (n = 146,891). Information on use of fertility drugs, borderline ovarian tumors and cancer diagnoses, covariates, emigration, and vital status was obtained by linkage to national registers. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) with adjustment for potential confounders for overall borderline ovarian tumors and for serous- and mucinous borderline ovarian tumors separately. RESULTS During a median 11.3 years of follow-up, 144 women developed a borderline ovarian tumor. No marked associations between ever use of clomiphene citrate, gonadotropins, gonadotropin-releasing hormone receptor modulators, human chorionic gonadotropin or progesterone and borderline ovarian tumors were observed, neither overall nor for serous and mucinous borderline ovarian tumors analysed separately. Further, no clear associations with borderline ovarian tumors were found according to cumulative dose, time since first use or parity status for any fertility drugs. CONCLUSIONS No marked associations between use of fertility drugs and borderline ovarian tumors were observed. However, the cohort's relatively young age at end of follow-up emphasizes the importance of extending the follow-up period for women who have used fertility drugs.
Collapse
Affiliation(s)
| | - Clarissa Lima Brown Frandsen
- Virus, Lifestyle and Genes, Danish Cancer Institute, 2100 Copenhagen, Denmark; Department of Obstetrics and Gynecology, Herlev University Hospital, 2730 Herlev, Denmark
| | - Bugge Nøhr
- Virus, Lifestyle and Genes, Danish Cancer Institute, 2100 Copenhagen, Denmark; Department of Obstetrics and Gynecology, Herlev University Hospital, 2730 Herlev, Denmark
| | - Jakob Hansen Viuff
- Diet, Cancer and Health, Danish Cancer Institute, 2100 Copenhagen, Denmark
| | - Marie Hargreave
- Virus, Lifestyle and Genes, Danish Cancer Institute, 2100 Copenhagen, Denmark
| | - Kirsten Frederiksen
- Statistics and Data Analysis, Danish Cancer Institute, 2100 Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Institute, 2100 Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Allan Jensen
- Virus, Lifestyle and Genes, Danish Cancer Institute, 2100 Copenhagen, Denmark.
| |
Collapse
|
3
|
Ozgür B, Puris E, Brachner A, Appelt-Menzel A, Oerter S, Balzer V, Holst MR, Christiansen RF, Hyldig K, Buckley ST, Kristensen M, Auriola S, Jensen A, Fricker G, Nielsen MS, Neuhaus W, Brodin B. Characterization of an iPSC-based barrier model for blood-brain barrier investigations using the SBAD0201 stem cell line. Fluids Barriers CNS 2023; 20:96. [PMID: 38115090 PMCID: PMC10731806 DOI: 10.1186/s12987-023-00501-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 12/07/2023] [Indexed: 12/21/2023] Open
Abstract
BACKGROUND Blood-brain barrier (BBB) models based on primary murine, bovine, and porcine brain capillary endothelial cell cultures have long been regarded as robust models with appropriate properties to examine the functional transport of small molecules. However, species differences sometimes complicate translating results from these models to human settings. During the last decade, brain capillary endothelial-like cells (BCECs) have been generated from stem cell sources to model the human BBB in vitro. The aim of the present study was to establish and characterize a human BBB model using human induced pluripotent stem cell (hiPSC)-derived BCECs from the hIPSC line SBAD0201. METHODS The model was evaluated using transcriptomics, proteomics, immunocytochemistry, transendothelial electrical resistance (TEER) measurements, and, finally, transport assays to assess the functionality of selected transporters and receptor (GLUT-1, LAT-1, P-gp and LRP-1). RESULTS The resulting BBB model displayed an average TEER of 5474 ± 167 Ω·cm2 and cell monolayer formation with claudin-5, ZO-1, and occludin expression in the tight junction zones. The cell monolayers expressed the typical BBB markers VE-cadherin, VWF, and PECAM-1. Transcriptomics and quantitative targeted absolute proteomics analyses revealed that solute carrier (SLC) transporters were found in high abundance, while the expression of efflux transporters was relatively low. Transport assays using GLUT-1, LAT-1, and LRP-1 substrates and inhibitors confirmed the functional activities of these transporters and receptors in the model. A transport assay suggested that P-gp was not functionally expressed in the model, albeit antibody staining revealed that P-gp was localized at the luminal membrane. CONCLUSIONS In conclusion, the novel SBAD0201-derived BBB model formed tight monolayers and was proven useful for studies investigating GLUT-1, LAT-1, and LRP-1 mediated transport across the BBB. However, the model did not express functional P-gp and thus is not suitable for the performance of drug efflux P-gp reletated studies.
Collapse
Affiliation(s)
- Burak Ozgür
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, DK-2100, Denmark
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, DK-2500, Denmark
| | - Elena Puris
- Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Heidelberg, Germany
| | - Andreas Brachner
- AIT - Austrian Institute of Technology GmbH, Vienna, 1210, Austria
| | - Antje Appelt-Menzel
- Chair Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, 97070, Würzburg, Germany
- Fraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies (TLC-RT) Röntgenring 11, 97070, Würzburg, Germany
| | - Sabrina Oerter
- Chair Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, 97070, Würzburg, Germany
- Fraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies (TLC-RT) Röntgenring 11, 97070, Würzburg, Germany
| | - Viktor Balzer
- Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Heidelberg, Germany
| | | | | | - Kathrine Hyldig
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, DK-2500, Denmark
- Department of Biomedicine, Aarhus University, Aarhus, DK-8000, Denmark
| | - Stephen T Buckley
- Global Research Technologies, Novo Nordisk A/S, Måløv, DK-2760, Denmark
| | - Mie Kristensen
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, DK-2100, Denmark
| | - Seppo Auriola
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland
| | - Allan Jensen
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, DK-2500, Denmark
| | - Gert Fricker
- Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Heidelberg, Germany
| | | | - Winfried Neuhaus
- AIT - Austrian Institute of Technology GmbH, Vienna, 1210, Austria
- Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, 3500, Austria
| | - Birger Brodin
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, DK-2100, Denmark.
| |
Collapse
|
4
|
Kawahara D, Jensen A, Yuan J, Nagata Y, Watanabe Y. Predicting the BRAF mutation with pretreatment MRI radiomics features for melanoma brain metastases receiving Gamma Knife radiosurgery. Clin Radiol 2023; 78:e934-e940. [PMID: 37690975 DOI: 10.1016/j.crad.2023.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 08/17/2023] [Accepted: 08/20/2023] [Indexed: 09/12/2023]
Abstract
AIM To develop a model using radiomics features extracted from magnetic resonance imaging (MRI) images of Gamma Knife radiosurgery (GKRS) to predict the BRAF mutation in patients with melanoma brain metastases (MBM). MATERIALS AND METHODS Data of 220 tumours were classified into two groups. One was a group whose BRAF mutation was identified, and the other group whose BRAF mutation was not identified. We extracted 1,962 radiomics features from gadolinium contrast-enhanced T1-weighted MRI treatment-planning images. Synthetic Minority Over-sampling TEchnique (SMOTE) was performed to address the unbalanced data-related issues. A single-layer neural network (NN) was used to build predictive models with radiomics features. The sensitivity, specificity, accuracy, and the area under the curve (AUC) were evaluated to assess the model performance. RESULTS The prediction performance for the final evaluation without the SMOTE had an accuracy of 77.14%, a specificity of 82.44%, a sensitivity of 81.85%, and an AUC of 0.79. The application of SMOTE improved the prediction model to an accuracy of 83.1%, a specificity of 87.07%, a sensitivity of 78.82%, and an AUC of 0.82. CONCLUSION The current study showed the feasibility of generating a highly accurate NN model for the BRAF mutation prediction. The prediction performance improved with SMOTE. The model assists physicians to obtain more accurate expectations of the treatment outcome without a genetic test.
Collapse
Affiliation(s)
- D Kawahara
- Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
| | | | - J Yuan
- Department of Radiation Oncology, University of Minnesota-Twin Cities, Minneapolis, MN, USA
| | - Y Nagata
- Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Watanabe
- Department of Radiation Oncology, University of Minnesota-Twin Cities, Minneapolis, MN, USA
| |
Collapse
|
5
|
Phung MT, Lee AW, McLean K, Anton-Culver H, Bandera EV, Carney ME, Chang-Claude J, Cramer DW, Doherty JA, Fortner RT, Goodman MT, Harris HR, Jensen A, Modugno F, Moysich KB, Pharoah PDP, Qin B, Terry KL, Titus LJ, Webb PM, Wu AH, Zeinomar N, Ziogas A, Berchuck A, Cho KR, Hanley GE, Meza R, Mukherjee B, Pike MC, Pearce CL, Trabert B. A framework for assessing interactions for risk stratification models: the example of ovarian cancer. J Natl Cancer Inst 2023; 115:1420-1426. [PMID: 37436712 PMCID: PMC10637032 DOI: 10.1093/jnci/djad137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 06/08/2023] [Accepted: 06/30/2023] [Indexed: 07/13/2023] Open
Abstract
Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a 4-criterion framework for assessing interactions that includes statistical, qualitative, biological, and practical approaches. We present the application of this framework in an ovarian cancer setting because this is an important step in developing more accurate risk stratification models. Using data from 9 case-control studies in the Ovarian Cancer Association Consortium, we conducted a comprehensive analysis of interactions among 15 unequivocal risk and protective factors for ovarian cancer (including 14 non-genetic factors and a 36-variant polygenic score) with age and menopausal status. Pairwise interactions between the risk/protective factors were also assessed. We found that menopausal status modifies the association among endometriosis, first-degree family history of ovarian cancer, breastfeeding, and depot-medroxyprogesterone acetate use and disease risk, highlighting the importance of understanding multiplicative interactions when developing risk prediction models.
Collapse
Affiliation(s)
- Minh Tung Phung
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Alice W Lee
- Department of Public Health, California State University, Fullerton, Fullerton, CA, USA
| | - Karen McLean
- Department of Gynecologic Oncology and Department of Pharmacology & Therapeutics, Elm & Carlton Streets, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Hoda Anton-Culver
- Department of Medicine, University of California, Irvine, Irvine, CA, USA
| | - Elisa V Bandera
- Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Michael E Carney
- Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Daniel W Cramer
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Jennifer Anne Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Renee T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Research, Cancer Registry of Norway, Oslo, Norway
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA
| | - Allan Jensen
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Francesmary Modugno
- Women’s Cancer Research Center, Magee-Women’s Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburg, PA, USA
| | - Kirsten B Moysich
- Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Paul D P Pharoah
- Department of Computational Biomedicine, Cedars-Sinai Medical Centre, Los Angeles, CA, USA
| | - Bo Qin
- Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Kathryn L Terry
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Linda J Titus
- Public Health, Muskie School of Public Service, University of Southern Maine, Portland, ME, USA
| | - Penelope M Webb
- Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Anna H Wu
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Nur Zeinomar
- Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Argyrios Ziogas
- Department of Medicine, University of California, Irvine, Irvine, CA, USA
| | - Andrew Berchuck
- Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA
| | - Kathleen R Cho
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Gillian E Hanley
- Department of Obstetrics & Gynecology, University of British Columbia Faculty of Medicine, Vancouver, BC, Canada
| | - Rafael Meza
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada
| | - Bhramar Mukherjee
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Malcolm C Pike
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Celeste Leigh Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Britton Trabert
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA
- Cancer Control and Populations Sciences Program, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
6
|
Holst MR, de Wit NM, Ozgür B, Brachner A, Hyldig K, Appelt-Menzel A, Sleven H, Cader Z, de Vries HE, Neuhaus W, Jensen A, Brodin B, Nielsen MS. Subcellular trafficking and transcytosis efficacy of different receptor types for therapeutic antibody delivery at the blood‒brain barrier. Fluids Barriers CNS 2023; 20:82. [PMID: 37932749 PMCID: PMC10626680 DOI: 10.1186/s12987-023-00480-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 10/18/2023] [Indexed: 11/08/2023] Open
Abstract
Here, we report an experimental setup to benchmark different receptors for targeted therapeutic antibody delivery at the blood-brain barrier. We used brain capillary endothelial-like cells derived from induced pluripotent stem cells (hiPSC-BECs) as a model system and compared them to colon epithelial Caco-2 cells. This approach helped to identify favourable receptors for transport into the cell layer itself or for directing transport for transcytosis across the cell layer. The sorting receptors transferrin receptor and sortilin were shown to be efficient as antibody cargo receptors for intracellular delivery to the cell layer. In contrast, the cell surface receptors CD133 and podocalyxin were identified as static and inefficient receptors for delivering cargo antibodies. Similar to in vivo studies, the hiPSC-BECs maintained detectable transcytotic transport via transferrin receptor, while transcytosis was restricted using sortilin as a cargo receptor. Based on these findings, we propose the application of sortilin as a cargo receptor for delivering therapeutic antibodies into the brain microvascular endothelium.
Collapse
Affiliation(s)
| | - Nienke Marije de Wit
- Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Amsterdam, The Netherlands
| | - Burak Ozgür
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, 2500, Copenhagen, Denmark
| | - Andreas Brachner
- AIT Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Centre for Health and Bioresources, Vienna, Austria
| | - Kathrine Hyldig
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, 2500, Copenhagen, Denmark
| | - Antje Appelt-Menzel
- Chair Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Röntgenring 11, Würzburg, Germany
- Translational Center Regenerative Therapies (TLC-RT), Fraunhofer Institute for Silicate Research ISC, Röntgenring 12, Würzburg, Germany
| | - Hannah Sleven
- Translational Molecular Neuroscience Group, University of Oxford, Oxford, UK
| | - Zameel Cader
- Translational Molecular Neuroscience Group, University of Oxford, Oxford, UK
| | - Helga Eveline de Vries
- Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Amsterdam, The Netherlands
| | - Winfried Neuhaus
- AIT Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Centre for Health and Bioresources, Vienna, Austria
- Department of Medicine, Faculty Medicine and Dentistry, Private Danube University, 3500, Krems, Austria
| | - Allan Jensen
- Biotherapeutic Discovery, H. Lundbeck A/S, Valby, 2500, Copenhagen, Denmark
| | - Birger Brodin
- Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
| | | |
Collapse
|
7
|
Frandsen CLB, Svendsen PF, Nøhr B, Viuff JH, Maltesen T, Kjaer SK, Jensen A. Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study. Int J Cancer 2023. [PMID: 37357906 DOI: 10.1002/ijc.34574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 04/28/2023] [Accepted: 05/09/2023] [Indexed: 06/27/2023]
Abstract
An association between polycystic ovary syndrome (PCOS) and epithelial ovarian tumors is biologically plausible as conditions inherent to PCOS such as excessive androgenic hormones, reproductive factors and obesity are also risk factors for these hormone-sensitive tumors. However, previous studies have showed conflicting results and have various methodological limitations. This population-based cohort study investigates the association between PCOS and epithelial ovarian tumors and includes all women born in Denmark between January 1, 1940 and December 31, 1993 (n = 1 719 304). PCOS diagnoses, ovarian cancer and borderline ovarian tumor diagnoses, covariates, migration and vital status were obtained from the Danish national registers. Adjusted cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CI) for epithelial ovarian cancer and for borderline ovarian tumors overall as well as for histological subtypes separately. During median 26 years of follow-up we identified 6490 women with ovarian cancer and 2990 women with borderline ovarian tumors. Overall, we observed no marked associations between a diagnosis of PCOS and overall epithelial ovarian cancer or overall epithelial borderline ovarian tumors, irrespective of time since diagnosis. However, we found an increased risk of ovarian cancer among postmenopausal women with PCOS (HR 2.28 95% CI 1.02-5.09) and an increased risk of serous borderline ovarian tumors (HR 2.34 95% CI 1.21-4.53) in women with PCOS compared with women without PCOS. Importantly, low statistical precision is a crucial limitation of our study and in previous studies and larger studies with longer follow-up are therefore warranted.
Collapse
Affiliation(s)
- Clarissa L B Frandsen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Obstetrics and Gynecology, University Hospital of Herlev and Gentofte, Copenhagen, Denmark
| | - Pernille F Svendsen
- Department of Obstetrics and Gynecology, University Hospital of Herlev and Gentofte, Copenhagen, Denmark
| | - Bugge Nøhr
- Department of Obstetrics and Gynecology, University Hospital of Herlev and Gentofte, Copenhagen, Denmark
| | - Jakob H Viuff
- Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Thomas Maltesen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjaer
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| |
Collapse
|
8
|
Bungay H, Jensen A, Holt N. Critical perspectives on Arts on Prescription. Perspect Public Health 2023:17579139231170776. [PMID: 37170835 DOI: 10.1177/17579139231170776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
The positive outcomes of engaging in the arts are increasingly reported in the research literature, supporting the use of the arts to enhance individual and community health and wellbeing. However, little attention is given to the less positive aspects of arts engagement. In some countries, healthcare practitioners and link workers can refer service-users experiencing mental health issues to social interventions such as Arts on Prescription (AoP) programmes. This critical review identifies problematic issues across such social prescriptions and AoP, including failures in arts and health projects, participants' negative experiences, and an absence of ethical guidelines for arts and health practice. Furthermore, it is evident that there is a lack of awareness and knowledge within healthcare systems, leading to inappropriate referrals, failure to take account of individual preferences, and a lack of communication between the third sector and healthcare services. Significantly, it is also unclear who holds the health responsibility for AoP participants. This article raises more questions than it answers, but for AoP to be effectively embedded in healthcare practice, the issues highlighted need to be addressed in order to safeguard participants and support the effective implementation of programmes more widely.
Collapse
Affiliation(s)
- H Bungay
- School of Allied and Public Health, Anglia Ruskin University, East Road, Cambridge CB1 1PT, UK
| | - A Jensen
- Primary Healthcare, Lund University, Lund, Sweden
- Aalborg University, Aalborg, Denmark
| | - N Holt
- Department of Health and Social Sciences, University of the West of England, Bristol, UK
| |
Collapse
|
9
|
May T, Bernardini M, Lheureux S, Aben KKH, Bandera EV, Beckmann MW, Benitez J, Berchuck A, Bjørge L, Carney ME, Cramer DW, deFazio A, Dörk T, Eccles DM, Friedlander M, García MJ, Goode EL, Hein A, Høgdall CK, Jensen A, Johnatty S, Kennedy CJ, Kiemeney LA, Kjær SK, Kupryjańczyk J, Matsuo K, McGuire V, Modugno F, Paddock LE, Pejovic T, Phelan CM, Riggan MJ, Rodriguez-Antona C, Rothstein JH, Sieh W, Song H, Terry KL, van Altena AM, Vanderstichele A, Vergote I, Thomsen LCV, Webb PM, Wentzensen N, Wilkens LR, Ziogas A, Jiang H, Tone A. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis. Can J Surg 2023; 66:E310-E320. [PMID: 37369443 PMCID: PMC10310341 DOI: 10.1503/cjs.017020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2021] [Indexed: 06/29/2023] Open
Abstract
BACKGROUND Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. METHODS We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. RESULTS Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. CONCLUSION This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
Collapse
Affiliation(s)
- Taymaa May
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Marcus Bernardini
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Stephanie Lheureux
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Katja K H Aben
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Elisa V Bandera
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Matthias W Beckmann
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Javier Benitez
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Andrew Berchuck
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Line Bjørge
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Michael E Carney
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Daniel W Cramer
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Anna deFazio
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Thilo Dörk
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Diana M Eccles
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Michael Friedlander
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - María Jose García
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Ellen L Goode
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Alexander Hein
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Claus K Høgdall
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Allan Jensen
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Sharon Johnatty
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Catherine J Kennedy
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Lambertus A Kiemeney
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Susanne K Kjær
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Jolanta Kupryjańczyk
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Keitaro Matsuo
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Valerie McGuire
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Francesmary Modugno
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Lisa E Paddock
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Tanja Pejovic
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Catherine M Phelan
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Marjorie J Riggan
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Cristina Rodriguez-Antona
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Joseph H Rothstein
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Weiva Sieh
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Honglin Song
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Kathryn L Terry
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Anne M van Altena
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Adriaan Vanderstichele
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Ignace Vergote
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Liv Cecilie Vestrheim Thomsen
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Penelope M Webb
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Nicolas Wentzensen
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Lynne R Wilkens
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Argyrios Ziogas
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Haiyan Jiang
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| | - Alicia Tone
- From the Division of Gynecologic Oncology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ont. (May, Bernardini, Tone); the Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ont. (May, Bernardini); the Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ont. (Lheureux); the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Johnatty); the Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Webb); the Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia (Friedlander); the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen Nuremberg, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany (Beckmann, Hein); the Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, Calif. (Fasching); the Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium (Vanderstichele, Vergote); the Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez, García, Rodriguez-Antona); the Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii (Carney); the Gynaecology Research Unit, Hannover Medical School, Hanover, Germany (Dörk); the Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Penn. (Modugno); the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Penn. (Modugno); the Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo); the Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo); the Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Jensen, Kjær); the Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Kjær); the Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. (Goode); the Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii (Wilkens); the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Fla. (Phelan); the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC (Berchuck, Riggan); the Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Mass. (Cramer, Terry); the Harvard T.H. Chan School of Public Health, Boston, Mass. (Cramer, Terry); the Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (Bandera); the New Jersey Department of Health and Senior Services, Mercerville, NJ (Paddock); the School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ (Paddock); the Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway (Bjørge, Vestrheim Thomsen); the Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands (Aben, Kiemeney); the Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands (Aben); the Department of Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands (van Altena); the Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Ore. (Pejovic); the Knight Cancer Institute, Oregon Health & Science University, Portland, Ore. (Pejovic); the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (Wentzensen); The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (C. Høgdall); the Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK (Song); the Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK (Eccles); the Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, Calif. (McGuire); the Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (Rothstein, Sieh); the Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, Calif. (Ziogas); the Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia (deFazio, Kennedy); the Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia (deFazio, Kennedy); the Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland (Kupryjanczyk); and the Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ont. (Jiang)
| |
Collapse
|
10
|
Jensen A, Bundesen B. Working together: the National Centre for Arts and Mental Health in Denmark. Perspect Public Health 2023; 143:129-130. [PMID: 37232250 DOI: 10.1177/17579139231157523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- A Jensen
- Senior Researcher, National Centre for Arts and Mental Health, Psykiatrisk Center Amager, Hans Bogbinders Allé 3, 2.tv. 2300 København S., Copenhagen, Denmark
| | - B Bundesen
- Director, National Centre for Arts and Mental Health, Copenhagen, Denmark
| |
Collapse
|
11
|
Gottschau M, Rosthøj S, Settnes A, Aalborg GL, Viuff JH, Munk C, Jensen A, Kjær SK, Mellemkjær L. Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy : A Nationwide Cohort Study. Ann Intern Med 2023; 176:596-604. [PMID: 37068275 DOI: 10.7326/m22-1628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2023] Open
Abstract
BACKGROUND More evidence is needed to substantiate current recommendations about removing ovaries during hysterectomy for benign conditions. OBJECTIVE To compare long-term outcomes in women with and without bilateral salpingo-oophorectomy (BSO) during hysterectomy for benign conditions. DESIGN Emulated target trial using data from a population-based cohort. SETTING Women in Denmark aged 20 years or older during 1977 to 2017. PARTICIPANTS 142 985 women with hysterectomy for a benign condition, 22 974 with BSO and 120 011 without. INTERVENTION Benign hysterectomy with or without BSO. MEASUREMENTS The primary outcomes were overall hospitalization for cardiovascular disease (CVD), overall cancer incidence, and all-cause mortality through December 2018. RESULTS Compared with women without BSO, women with BSO who were younger than 45 years at surgery had a higher 10-year cumulative risk for hospitalization for CVD (risk difference [RD], 1.19 percentage points [95% CI, 0.09 to 2.43 percentage points]). Women with BSO had a higher 10-year cumulative risk for cancer for ages 45 to 54 years (RD, 0.73 percentage point [CI, 0.05 to 1.38 percentage points]), 55 to 64 years (RD, 1.92 percentage points [CI, 0.69 to 3.25 percentage points]), and 65 years or older (RD, 2.54 percentage points [CI, 0.91 to 4.25 percentage points]). Women with BSO had higher 10-year mortality in all age groups, although the differences were statistically significant only for ages 45 to 54 years (RD, 0.79 percentage point [CI, 0.27 to 1.30 percentage points]). The mortality at 20 years was inconsistent with that at 10 years in women aged 65 years or older. LIMITATION Age was a proxy for menopausal status. CONCLUSION The authors find that these results support current recommendations for conserving ovaries in premenopausal women without a high risk for ovarian cancer and suggest a cautious approach in postmenopausal women. PRIMARY FUNDING SOURCE The Danish Cancer Society's Scientific Committee and the Mermaid Project.
Collapse
Affiliation(s)
- Mathilde Gottschau
- Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark (M.G., J.H.V., L.M.)
| | - Susanne Rosthøj
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark (S.R., G.L.A.)
| | - Annette Settnes
- Department of Obstetrics and Gynecology, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark (A.S.)
| | - Gitte Lerche Aalborg
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark (S.R., G.L.A.)
| | - Jakob Hansen Viuff
- Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark (M.G., J.H.V., L.M.)
| | - Christian Munk
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (C.M.)
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark (A.J.)
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, and Department of Gynecology, Rigshospitalet University Hospital, University of Copenhagen, Copenhagen, Denmark (S.K.K.)
| | - Lene Mellemkjær
- Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark (M.G., J.H.V., L.M.)
| |
Collapse
|
12
|
Stergiou N, Wuensche TE, Schreurs M, Mes I, Verlaan M, Kooijman EJM, Windhorst AD, Helboe L, Vergo S, Christensen S, Asuni AA, Jensen A, Van Dongen GAMS, Bang-Andersen B, Vugts DJ, Beaino W. Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody. Eur J Nucl Med Mol Imaging 2023; 50:1306-1317. [PMID: 36635462 PMCID: PMC10027647 DOI: 10.1007/s00259-023-06109-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 01/05/2023] [Indexed: 01/14/2023]
Abstract
PURPOSE The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer's disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques for brain imaging of antibodies may guide decision-making in the future but needs further development. In this study, we used 89Zr-immuno-PET to evaluate the targeting and distribution of a bispecific brain-shuttle IgG based on Adu with transferrin receptor protein-1 (TfR1) shuttling mechanism, mAbAdu-scFab8D3, designated Adu-8D3, as a candidate theranostic for AD. We also validated the 89Zr-immuno-PET platform as an enabling technology for developing new antibody-based theranostics for brain disorders. METHODS Adu, Adu-8D3, and the non-binding control construct B12-8D3 were modified with DFO*-NCS and radiolabeled with 89Zr. APP/PS1 mice were injected with 89Zr-labeled mAbs and imaged on days 3 and 7 by positron emission tomography (PET). Ex vivo biodistribution was performed on day 7, and ex vivo autoradiography and immunofluorescence staining were done on brain tissue to validate the PET imaging results and target engagement with amyloid-β plaques. Additionally, [89Zr]Zr-DFO*-Adu-8D3 was evaluated in 3, 7, and 10-month-old APP/PS1 mice to test its potential in early stage disease. RESULTS A 7-fold higher brain uptake was observed for [89Zr]Zr-DFO*-Adu-8D3 compared to [89Zr]Zr-DFO*-Adu and a 2.7-fold higher uptake compared to [89Zr]Zr-DFO*-B12-8D3 on day 7. Autoradiography and immunofluorescence of [89Zr]Zr-DFO*-Adu-8D3 showed co-localization with amyloid plaques, which was not the case with the Adu and B12-8D3 conjugates. [89Zr]Zr-DFO*-Adu-8D3 was able to detect low plaque load in 3-month-old APP/PS1 mice. CONCLUSION 89Zr-DFO*-immuno-PET revealed high and specific uptake of the bispecific Adu-8D3 in the brain and can be used for the early detection of Aβ plaque pathology. Here, we demonstrate that 89Zr-DFO*-immuno-PET can be used to visualize and quantify brain uptake of mAbs and contribute to the evaluation of biological therapeutics for brain diseases.
Collapse
Affiliation(s)
- N Stergiou
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - T E Wuensche
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - M Schreurs
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - I Mes
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - M Verlaan
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - E J M Kooijman
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - A D Windhorst
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - L Helboe
- H. Lundbeck A/S, Copenhagen, Denmark
| | - S Vergo
- H. Lundbeck A/S, Copenhagen, Denmark
| | | | - A A Asuni
- H. Lundbeck A/S, Copenhagen, Denmark
| | - A Jensen
- H. Lundbeck A/S, Copenhagen, Denmark
| | - G A M S Van Dongen
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | | | - D J Vugts
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
| | - W Beaino
- Radiology & Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands.
| |
Collapse
|
13
|
Gottschau M, Kjær SK, Viuff JH, Jensen A, Munk C, Settnes A, Mellemkjær L. Ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study. Breast Cancer Res Treat 2023; 197:583-591. [PMID: 36482232 DOI: 10.1007/s10549-022-06825-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 11/30/2022] [Indexed: 12/14/2022]
Abstract
PURPOSE To evaluate whether previous ovarian removal concomitant with benign hysterectomy improves prognosis in a cohort of women with breast cancer. METHODS In this nationwide register-based cohort study, risk of recurrence and mortality were examined in 4563 women with invasive breast cancer and previous bilateral salpingo-oophorectomy (BSO) concomitant with benign hysterectomy, during 1977-2018. Comparing with benign hysterectomy alone, hazard ratios (HRs) and 95% confidence intervals (CIs) were evaluated by Cox-proportional hazards regression models. Analyses were stratified on age at hysterectomy as a proxy for menopausal status (< 45, 45-54 and ≥ 55 years); tumor characteristics, estrogen receptor (ER)-status, and use of hormone therapy (HT) were included in multivariable models. RESULTS Compared with hysterectomy alone, premenopausal (< 45 years) BSO at benign hysterectomy was associated with an age and calendar period adjusted HR of 1.48 (95% CI 0.83-2.65) for breast cancer recurrence within 10 years of follow-up, a HR of 1.07 (95% CI 0.66-1.72) for overall mortality after breast cancer, and a HR of 0.59 (95% CI 0.26-1.32) for breast cancer-specific mortality. The corresponding HRs for postmenopausal (≥ 55 years) BSO at benign hysterectomy were 1.51 (95% CI 0.73-3.12) for recurrences, 1.34 (95% CI 0.74-2.44) for overall mortality, and 1.78 (95% CI 0.74-4.30) for breast cancer mortality. Adjusting for tumor characteristics, ER-status and HT did not alter the results. CONCLUSION Results from this cohort study did not indicate an improvement in breast cancer prognosis when removing the ovaries at benign hysterectomy prior to the cancer diagnosis.
Collapse
Affiliation(s)
- Mathilde Gottschau
- Diet, Cancer and Health, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark
- Department of Gynecology, Rigshospitalet University Hospital, University of Copenhagen, 2100, Copenhagen, Denmark
| | - Jakob Hansen Viuff
- Diet, Cancer and Health, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Genes, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark
| | - Christian Munk
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark
| | - Annette Settnes
- Department of Obstetrics and Gynecology, North Zealand Hospital, University of Copenhagen, 3400, Hillerød, Denmark
| | - Lene Mellemkjær
- Diet, Cancer and Health, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.
| |
Collapse
|
14
|
DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J, Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubiński J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. J Natl Cancer Inst 2022; 114:1533-1544. [PMID: 36210504 PMCID: PMC9949586 DOI: 10.1093/jnci/djac160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 04/13/2022] [Accepted: 08/18/2022] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. METHODS Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. RESULTS We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. CONCLUSIONS CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
Collapse
Grants
- P01 CA017054 NCI NIH HHS
- UM1 CA176726 NCI NIH HHS
- R01 CA058860 NCI NIH HHS
- P50 CA105009 NCI NIH HHS
- R01-CA122443 NIH HHS
- 076113 Wellcome Trust
- G0401527 Medical Research Council
- U19-CA148112 NCI NIH HHS
- N01 CN025403 NCI NIH HHS
- P50 CA136393 NCI NIH HHS
- C490/A10119 C490/A10124 Cancer Research UK
- 1000143 Medical Research Council
- R01-CA54419 NIH HHS
- C8221/A19170 Cancer Research UK
- R01 CA049449 NCI NIH HHS
- P50 CA159981 NCI NIH HHS
- T32 GM118288 NIGMS NIH HHS
- CA1X01HG007491-01 NIH HHS
- Z01-ES044005 NIEHS NIH HHS
- R01 CA106414 NCI NIH HHS
- R01 CA095023 NCI NIH HHS
- N01 PC067010 NCI NIH HHS
- R01 CA058598 NCI NIH HHS
- U01 CA176726 NCI NIH HHS
- S10 RR025141 NCRR NIH HHS
- M01 RR000056 NCRR NIH HHS
- Department of Health
- 5T32GM118288-03 NIH HHS
- MR/N003284/1 Medical Research Council
- P30 CA014089 NCI NIH HHS
- K07-CA080668 NCI NIH HHS
- 14136 Cancer Research UK
- Worldwide Cancer Research
- MR_UU_12023 Medical Research Council
- R01 CA067262 NCI NIH HHS
- UM1 CA186107 NCI NIH HHS
- P30 CA015083 NCI NIH HHS
- G1000143 Medical Research Council
- R01 CA076016 NCI NIH HHS
- NHGRI NIH HHS
- P01 CA087969 NCI NIH HHS
- R01- CA61107 NCI NIH HHS
- R01-CA58598 NIH HHS
- U19 CA148112 NCI NIH HHS
- ULTR000445 NCATS NIH HHS
- R03 CA115195 NCI NIH HHS
- Wellcome Trust
- Breast Cancer Now
- R01 CA160669 NCI NIH HHS
- R01-CA058860 NIH HHS
- MC_UU_00004/01 Medical Research Council
- C570/A16491 Cancer Research UK
- R01-CA76016 NIH HHS
- R01-CA106414-A2 NIH HHS
- 001 World Health Organization
- Z01 ES049033 Intramural NIH HHS
- R01 CA126841 NCI NIH HHS
- MR/M012190/1 Medical Research Council
- 209057 Wellcome Trust
- R03 CA113148 NCI NIH HHS
- R01 CA149429 NCI NIH HHS
- National Institute of General Medical Sciences
- National Institutes of Health
- CSMC Precision Health Initiative
- Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation
- Ovarian Cancer Research Fund thanks
- National Cancer Institute
- National Human Genome Research Institute
- Canadian Institutes of Health Research
- Ovarian Cancer Research Fund
- European Commission’s Seventh Framework Programme
- Army Medical Research and Materiel Command
- National Health & Medical Research Council of Australia
- Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia
- Ovarian Cancer Australia
- Peter MacCallum Foundation
- University of Erlangen-Nuremberg
- National Kankerplan
- Breast Cancer Now, Institute of Cancer Research
- National Center for Advancing Translational Sciences
- European Commission
- International Agency for Research on Cancer
- Danish Cancer Society
- Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale
- Institut National de la Santé et de la Recherche Médicale
- German Cancer Aid; German Cancer Research Center
- Federal Ministry of Education and Research
- Hellenic Health Foundation
- Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy
- National Research Council
- Dutch Ministry of Public Health, Welfare and Sports
- Netherlands Cancer Registry
- LK Research Funds
- Dutch Prevention Funds
- World Cancer Research Fund
- Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health
- Health Research Fund
- Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra
- Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten
- German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research
- German Cancer Research Center
- Rudolf-Bartling Foundation
- Helsinki University Hospital Research Fund
- University of Pittsburgh School of Medicine Dean’s Faculty Advancement Award
- Department of Defense
- NCI
- Swedish Cancer Society, Swedish Research Council, Beta Kamprad Foundation
- Danish Cancer Society, Copenhagen
- Mayo Foundation
- Minnesota Ovarian Cancer Alliance
- Fred C. and Katherine B. Andersen Foundation
- VicHealth and Cancer Council Victoria, Cancer Council Victoria
- National Health and Medical Research Council of Australia
- NHMRC
- DOD Ovarian Cancer Research Program
- Moffitt Cancer Center
- Merck Pharmaceuticals
- Radboud University Medical Centre
- UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge
- National Institute of Environmental Health Sciences
- The Swedish Cancer Foundation
- the Swedish Research Council
- American Cancer Society
- Celma Mastry Ovarian Cancer Foundation
- Lon V Smith Foundation
- The Eve Appeal
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- California Cancer Research Program
- National Science Centre
- NIH
Collapse
Affiliation(s)
- Amber A DeVries
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Joe Dennis
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Jonathan P Tyrer
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Pei-Chen Peng
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Simon G Coetzee
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Alberto L Reyes
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Jasmine T Plummer
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Brian D Davis
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Stephanie S Chen
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Felipe Segato Dezem
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Katja K H Aben
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Hoda Anton-Culver
- Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA
| | - Natalia N Antonenkova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
| | - Matthias W Beckmann
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany
| | - Alicia Beeghly-Fadiel
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Andrew Berchuck
- Department of Gynecologic Oncology, Duke University Hospital, Durham, NC, USA
| | - Natalia V Bogdanova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
- Department of Radiation Oncology, Hannover Medical School, Hannover, Germany
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | | | - James D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Ralf Butzow
- Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Ian Campbell
- Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Linda S Cook
- Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA
- Community Health Sciences, University of Calgary, Calgary, AB, Canada
| | - Anna DeFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia
- The Daffodil Centre, a joint venture with Cancer Council NSW, The University of Sydney, Sydney, New South Wales, Australia
| | - Jennifer A Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Thilo Dörk
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Diana M Eccles
- Faculty of Medicine, University of Southampton, Southampton, UK
| | - A Heather Eliassen
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Peter A Fasching
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA
| | - Renée T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Graham G Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Ellen L Goode
- Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Niclas Håkansson
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | | | - Chad Huff
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David G Huntsman
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
| | - Allan Jensen
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Siddhartha Kar
- Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- Section of Translational Epidemiology, Division of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Beth Y Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA
| | - Elza K Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia
- Saint Petersburg State University, Saint Petersburg, Russia
| | - Lambertus A Kiemeney
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Susanne K Kjaer
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Jolanta Kupryjanczyk
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Marilyne Labrie
- Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
| | - Diether Lambrechts
- VIB Center for Cancer Biology, VIB, Leuven, Belgium
- Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Nhu D Le
- Cancer Control Research, BC Cancer, Vancouver, BC, Canada
| | - Jan Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Taymaa May
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Usha Menon
- MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Francesmary Modugno
- Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Alvaro N Monteiro
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Kirsten B Moysich
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - Kunle Odunsi
- Department of Oncology, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA
- Department of Obstetrics and Gynecology, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA
| | - Håkan Olsson
- Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Celeste L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Tanja Pejovic
- Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
- Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA
| | - Susan J Ramus
- School of Women's and Children's Health, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia
| | | | - Marjorie J Riggan
- Department of Gynecologic Oncology, Duke University Hospital, Durham, NC, USA
| | - Isabelle Romieu
- Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Dale P Sandler
- Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - Joellen M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - V Wendy Setiawan
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Weiva Sieh
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Honglin Song
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Rebecca Sutphen
- Epidemiology Center, College of Medicine, University of South Florida, Tampa, FL, USA
| | - Kathryn L Terry
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Pamela J Thompson
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Linda Titus
- Muskie School of Public Policy, Public Health, Portland, ME, USA
| | - Shelley S Tworoger
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Els Van Nieuwenhuysen
- Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium
| | - Digna Velez Edwards
- Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Penelope M Webb
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Alice S Whittemore
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA
- Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA
| | - Alicja Wolk
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Argyrios Ziogas
- Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA
| | - Matthew L Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Kate Lawrenson
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women's Cancer Program at the Samuel Oschin Cancer Institute Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Simon A Gayther
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Michelle R Jones
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
15
|
Phung MT, Muthukumar A, Trabert B, Webb PM, Jordan SJ, Terry KL, Cramer DW, Titus LJ, Risch HA, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich KB, Jensen A, Kjaer SK, Anton-Culver H, Ziogas A, Berchuck A, Khoja L, Wu AH, Pike MC, Pearce CL, Lee AW. Effects of risk factors for ovarian cancer in women with and without endometriosis. Fertil Steril 2022; 118:960-969. [PMID: 36182623 PMCID: PMC9969849 DOI: 10.1016/j.fertnstert.2022.07.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 07/16/2022] [Accepted: 07/19/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis. DESIGN Pooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium. SETTING Population-based. PATIENT(S) We included 8,500 women with ovarian cancer, 13,592 control women. INTERVENTION(S) Ten well-established ovarian cancer risk factors. MAIN OUTCOME MEASURE(S) Risk of ovarian cancer for women with and without endometriosis. RESULT(S) Most risk factor-ovarian cancer associations were similar when comparing women with and without endometriosis, and no interactions were statistically significant. However, body mass index (BMI) 25-<30 kg/m2 was associated with increased ovarian cancer risk among women with endometriosis (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.00-1.60), but not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05) when compared with BMI 18.5-<25 kg/m2; an increased risk was observed for a BMI ≥30 kg/m2, although there was little difference comparing women with endometriosis (OR = 1.21; 95% CI, 0.94-1.57) to women without (OR = 1.13; 95% CI, 1.04-1.22) (P-interaction = .51). Genital talcum powder use and long-term menopausal estrogen-only therapy use showed increased ovarian cancer risk, but risk appeared greater for those with endometriosis vs. those without (genital talcum powder: OR = 1.38; 95% CI, 1.04-1.84 vs. OR = 1.12; 95% CI, 1.01-1.25, respectively; ≥10 years of estrogen-only therapy: OR = 1.88; 95% CI, 1.09-3.24 vs. OR = 1.42; 95% CI, 1.14-1.76, respectively); neither of these interactions were statistically significant (P-interaction = .65 and P-interaction = .96, respectively). CONCLUSION(S) The associations between ovarian cancer and most risk factors were similar among women with and without endometriosis. However, there was some suggestion of differences by endometriosis status for BMI, menopausal hormone therapy use, and genital talcum powder use, highlighting the complexity of ovarian cancer etiology.
Collapse
Affiliation(s)
- Minh Tung Phung
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
| | - Aruna Muthukumar
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
| | - Britton Trabert
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah; Cancer Control and Population Sciences Program, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
| | - Penelope M Webb
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Susan J Jordan
- University of Queensland, School of Public Health, Brisbane, Queensland, Australia
| | - Kathryn L Terry
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Daniel W Cramer
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Linda J Titus
- Public Health, Muskie School of Public Service, University of Southern Maine, Portland, Maine
| | - Harvey A Risch
- Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
| | - Jennifer Anne Doherty
- Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Holly R Harris
- Division of Public Health Sciences, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California; Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Francesmary Modugno
- Womens Cancer Research Program, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Kirsten B Moysich
- Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
| | - Allan Jensen
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Hoda Anton-Culver
- Department of Medicine, University of California, Irvine, Irvine, California
| | - Argyrios Ziogas
- Department of Medicine, University of California, Irvine, Irvine, California
| | - Andrew Berchuck
- Division of Gynecologic Oncology, Duke University School of Medicine, Durham, North Carolina
| | - Lilah Khoja
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
| | - Anna H Wu
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Malcolm C Pike
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Celeste Leigh Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
| | - Alice W Lee
- Department of Public Health, California State University, Fullerton, Fullerton, California.
| |
Collapse
|
16
|
Wuensche TE, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman EJM, Janssen B, Windhorst AD, Jensen A, Asuni AA, Bang-Andersen B, Beaino W, Dongen GAMS, Vugts DJ. Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential. Theranostics 2022; 12:7067-7079. [PMID: 36276653 PMCID: PMC9576608 DOI: 10.7150/thno.73509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 08/27/2022] [Indexed: 11/05/2022] Open
Abstract
The accelerated approval of the monoclonal antibody (mAb) aducanumab as a treatment option for Alzheimer's Disease and the continued discussions about its efficacy have shown that a better understanding of immunotherapy for the treatment of neurodegenerative diseases is needed. 89Zr-immuno-PET could be a suitable tool to open new avenues for the diagnosis of CNS disorders, monitoring disease progression, and assessment of novel therapeutics. Herein, three different 89Zr-labeling strategies and direct radioiodination with 125I of a bispecific anti-amyloid-beta aducanumab derivate, consisting of aducanumab with a C-terminal fused anti-transferrin receptor binding single chain Fab fragment derived from 8D3 (Adu-8D3), were compared ex vivo and in vivo with regard to brain uptake and target engagement in an APP/PS1 Alzheimer's disease mouse model and wild type animals. Methods: Adu-8D3 and a negative control antibody, based on the HIV specific B12 antibody also carrying C-terminal fused 8D3 scFab (B12-8D3), were each conjugated with NCS-DFO, NCS-DFO*, or TFP-N-suc-DFO-Fe-ester, followed by radiolabeling with 89Zr. 125I was used as a substitute for 124I for labeling of both antibodies. 30 µg of radiolabeled mAb, corresponding to approximately 6 MBq 89Zr or 2.5 MBq 125I, were injected per mouse. PET imaging was performed 1, 3 and 7 days post injection (p.i.). All mice were sacrificed on day 7 p.i. and subjected to ex vivo biodistribution and brain autoradiography. Immunostaining on brain tissue was performed after autoradiography for further validation. Results:Ex vivo biodistribution revealed that the brain uptake of [89Zr]Zr-DFO*-NCS-Adu-8D3 (2.19 ±0.12 %ID/g) was as high as for its 125I-analog (2.21 ±0.15 %ID/g). [89Zr]Zr-DFO-NCS-Adu-8D3 and [89Zr]Zr-DFO-N-suc-Adu-8D3 showed significantly lower uptake (< 0.65 %ID/g), being in the same range as for the 89Zr-labeled controls (B12-8D3). Autoradiography of [89Zr]Zr-DFO*-NCS-Adu-8D3 and [125I]I-Adu-8D3 showed an amyloid-beta related granular uptake pattern of radioactivity. In contrast, the [89Zr]Zr-DFO-conjugates and the control antibody groups did not show any amyloid-beta related uptake pattern, indicating that DFO is inferior for 89Zr-immuno-PET imaging of the brain in comparison to DFO* for Adu-8D3. This was confirmed by day 7 PET images showing only amyloid-beta related brain uptake for [89Zr]Zr-DFO*-NCS-Adu-8D3. In wild type animals, such an uptake was not observed. Immunostaining showed a co-localization of all administered Adu-8D3 conjugates with amyloid-beta plaques. Conclusion: We successfully demonstrated that 89Zr-immuno-PET is suitable for imaging and quantifying amyloid-beta specific brain uptake using a bispecific aducanumab brain shuttling antibody, Adu-8D3, but only when using the novel chelator DFO*, and not DFO, for labeling with 89Zr.
Collapse
Affiliation(s)
- Thomas E Wuensche
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Natascha Stergiou
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Iris Mes
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Mariska Verlaan
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Maxime Schreurs
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Esther J M Kooijman
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Bart Janssen
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Albert D Windhorst
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.,Amsterdam Neuroscience, Brain imaging, Amsterdam, The Netherlands
| | - Allan Jensen
- H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark
| | | | | | - Wissam Beaino
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.,Amsterdam Neuroscience, Brain imaging, Amsterdam, The Netherlands
| | - Guus A M S Dongen
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.,Amsterdam Neuroscience, Brain imaging, Amsterdam, The Netherlands
| | - Danielle J Vugts
- Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.,Amsterdam Neuroscience, Brain imaging, Amsterdam, The Netherlands
| |
Collapse
|
17
|
Møller M, Kjær SK, Lindquist S, Brown Frandsen CL, Albieri V, Viuff JH, Nøhr B, Olsen A, Jensen A. Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility. Fertil Steril 2022; 118:738-747. [PMID: 36041966 DOI: 10.1016/j.fertnstert.2022.06.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 06/15/2022] [Accepted: 06/21/2022] [Indexed: 01/13/2023]
Abstract
OBJECTIVE To study the association between use of fertility drugs and colorectal cancer among women with infertility. DESIGN Population-based cohort study. SETTING Not applicable. PATIENT(S) The study cohort was obtained from the Danish Infertility Cohort and consisted of all women with infertility aged 20-45 years living in Denmark during 1995-2017. INTERVENTION(S) Information on the use of specific types of fertility drugs, colorectal cancer diagnoses, covariates, and vital status were obtained from the Danish Infertility Cohort and Danish national registers. MAIN OUTCOME MEASURE(S) Cox proportional hazard models adjusted for potential confounders were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for colorectal cancer overall and rectal and colon cancer separately. RESULTS(S) Among 148,036 women in the final study cohort, 205 women were diagnosed with colorectal cancer. Ever use of clomiphene citrate (CC) was associated with a lower rate of colorectal cancer (unadjusted HR, 0.67; 95% CI, 0.51-0.89; adjusted HR, 0.68; 95% CI, 0.50-0.93). However, the lower rate was only seen among women who first used CC >8 years ago (unadjusted HR, 0.56; 95% CI, 0.41-0.76; adjusted HR, 0.52; 95% CI, 0.36-0.75). No marked associations were found between the use of any of other types of fertility drugs and colorectal cancer. The results for colon and rectal cancer analyzed separately were similar, except for a suggestion of a decreased risk of rectal cancer associated with the use of gonadotropins (adjusted HR, 0.46; 95% CI, 0.20-1.08). CONCLUSION(S) Among women with infertility, the use of most types of fertility drugs was not associated with colorectal cancer. However, CC may decrease the risk of colorectal cancer and gonadotropins might decrease the risk of rectal cancer, but we cannot rule out that these findings may be more related to the underlying conditions in these women or are chance findings. Consequently, the results from this study should be investigated further in large epidemiological studies.
Collapse
Affiliation(s)
- Maria Møller
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Sofie Lindquist
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | | | - Vanna Albieri
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Jakob Hansen Viuff
- Diet, Cancer and Health, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Bugge Nøhr
- The Fertility Clinic, Department of Obstetrics and Gynecology, Copenhagen University Hospital Herlev, Herlev, Denmark
| | - Anja Olsen
- Nutrition and Biomarkers, Danish Cancer Society Reseach Center, Copenhagen, Denmark; Institute of Public Health, Aarhus University, Aarhus, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark.
| |
Collapse
|
18
|
Frandsen CLB, Jensen A, Poulsen FR, Møller M, Albieri V, Lindquist S, Nøhr B, Kjær SK. O-083 Tumors of the central nervous system among women treated with fertility drugs: a population-based cohort study. Hum Reprod 2022. [DOI: 10.1093/humrep/deac104.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Is the use of fertility drugs among infertile women associated with tumors of the central nervous system (CNS)?
Summary answer
The use of most specific types of fertility drugs is not associated with an increased risk of CNS tumors overall.
What is known already
Few previous studies have investigated the association between fertility drugs and CNS tumors. Studies have reported inconsistent results regarding the risk of CNS tumors associated with assisted reproductive technologies such as in vitro fertilization (IVF). No studies have reported the risk associated with various specific fertility drugs.
Study design, size, duration
Retrospective population-based cohort study of all women included in the Danish Infertility Cohort. The study cohort consisted of 148 016 infertile women after exclusion of women who emigrated, died, were diagnosed with cancer before infertility diagnosis, and women for whom information on level of education was missing. The cohort was linked to various national health- and civil registers to study all 20- to 45-year old infertile women in Denmark during 1995-2017.
Participants/materials, setting, methods
The study cohort was linked to various national health and population registers to obtain information on fertility drugs (clomiphene citrate, gonadotropins, human chorionic gonadotropin, gonadotropin-releasing hormone receptor modulators and progesterone), CNS tumors, relevant covariates and vital and emigration status. Cox proportional hazard regression models were used to calculate hazard ratios and 95% confidence intervals for CNS tumors overall and for gliomas, meningiomas and diverse benign tumors of the brain and other parts of the CNS.
Main results and the role of chance
During a median 11.3 years of follow-up, 328 women were diagnosed with a CNS tumor. No marked associations were observed between use of most types of fertility drugs (clomiphene citrate, gonadotropins, gonadotropin releasing hormone receptor modulators and progesterone) and CNS tumors. However, ever use of human chorionic gonadotropin was associated with an increased rate of gliomas (HR 2.13 95% CI 0.90-5.01) but a decreased rate of meningiomas (HR 0.49 95% CI 0.28-0.87). No clear associations with CNS tumors were observed according to time since first use or cumulative dose for any specific fertility drugs. Additional studies with longer follow-up are necessary to support these findings.
Limitations, reasons for caution
The median age at end of follow-up (43.5 years) was lower than the median age for CNS tumors diagnosis (60 years). Information on estrogen use, treatment regimens and number of cycles is only partly available in the registers and these were not included in this study.
Wider implications of the findings
This study presents reassuring results regarding the risk of tumors of the CNS among women treated with fertility drugs. Our study is only generalizable to premenopausal women, and the risk for postmenopausal women remains to be assessed.
Trial registration number
not applicable
Collapse
Affiliation(s)
- C L B Frandsen
- Danish Cancer Society Research Center, Lifestyle- Reproduction and Cancer, Copenhagen , Denmark
- Copenhagen University Hospital Herlev, Department of Obstetrics and Gynecology, Herlev , Denmark
| | - A Jensen
- Danish Cancer Society Research Center, Lifestyle- Reproduction and Cancer, Copenhagen , Denmark
| | - F R Poulsen
- Odense University Hospital, Department of Neurosurgery, Odensen , Denmark
- University of Southern Denmark, Department of Clinical Research and Bridge Brain Research Inter Disciplinary Guided Excellence, Odense , Denmark
| | - M Møller
- Danish Cancer Society Research Center, Lifestyle- Reproduction and Cancer, Copenhagen , Denmark
| | - V Albieri
- Danish Cancer Society Research Center, Statistics and Data Analysis, Copenhagen , Denmark
| | - S Lindquist
- Danish Cancer Society Research Center, Virus- Lifestyle and Genes, Copenhagen , Denmark
| | - B Nøhr
- Copenhagen University Hospital Herlev, Department of Obstetrics and Gynecology, Herlev , Denmark
| | - S K Kjær
- Danish Cancer Society Research Center, Virus- Lifestyle and Genes, Copenhagen , Denmark
- Rigshospitalet- University of Copenhagen, Department of Gynecology, Copenahgen , Denmark
| |
Collapse
|
19
|
Jensen A, Guleria S, Albieri V, Nøhr B, Frederiksen K, Kjær S. P-783 Fertility treatment and risk of ovarian cancer in a large nationwide cohort of 151,821 infertile Danish women. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Do use of fertility drugs increase the risk of ovarian cancer among infertile women
Summary answer
Use certain types of fertility drugs may modify the risk of ovarian cancer among infertile women, primarily for serous ovarian tumors and among parous women.
What is known already
Even though most previous studies on the association between fertility treatment and ovarian cancer have not been able to show a convincing association, some studies have found an increased risk of this malignancy among women undergoing fertility treatment. However, many of the previous studies have had methodological limitations including selection bias and potential confounding due to missing information of important factors, such as parity status and hormonal contraceptive use, small sample size as well as short- and incomplete follow-up time. Furthermore, only few studies have assessed the association between fertility treatment and ovarian cancer according to histological type.
Study design, size, duration
This retrospective register-based cohort study included virtually all 20-45 year old infertile women in Denmark between 1971 and 2017 as identified in the Danish Infertility Cohort. All women were followed from entry in the cohort (i.e. the date of first infertility diagnosis) to occurrence of ovarian cancer, any other cancer (except non-melanoma skin cancer), death, emigration, bilateral oophorectomy or end of follow-up (December 31, 2017), whichever occurred first. The median follow-up length was 10.3 years
Participants/materials, setting, methods
In total, 332 women were diagnosed with ovarian cancer during the follow-up period. Information on the use of specific fertility drugs (clomiphene citrate, gonadotropins, hCGs, GnRH receptor modulators and progesterone), ovarian cancer, covariates and vital status was obtained from the Danish Infertility Cohort and various Danish national registers. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% CIs for ovarian cancer overall and for serous ovarian tumors.
Main results and the role of chance
After adjustment for attained age (as the underlying time scale), calendar year of study entry, highest obtained level of education, maternal age at first childbirth, number of childbirths, hormonal contraceptive use as well as mutual adjustment for treatment with any other specific fertility drugs, ever use of hCG (HR 0.62, 95% CI 0.44-0.89) and GnRH receptor modulators (HR 0.63, 95% CI 0.40-1.00) were associated with a decreased risk of overall ovarian cancer. In contrast, ever use of gonadotropins (HR 1.43; 95% CI 0.91-2.24) and especially progesterone (HR 1.81; 95% CI 1.18-2.78) increased the risk of overall ovarian cancer. No marked association was observed for clomiphene citrate (HR 1.07, 95% CI 0.80-1.44)). The rates for serous ovarian cancer generally resembled those observed for overall ovarian cancer; however only the association for progesterone reached statistical significance (HR 2.89; 95% CI 1.67-4.99). The observed associations existed mainly among parous women and did not vary with time since first use of the fertility drug in question and no statistically significant associations were observed with cumulative dose of the specific fertility drugs.
Limitations, reasons for caution
The median age at the end of follow-up was only 42.5 years, which is markedly lower than the usual peak age for ovarian cancer in Denmark (mid 60s). Hence, we were not able to capture the true, potential long-term association between use of fertility drugs and ovarian cancer.
Wider implications of the findings
Use of certain specific types of fertility drugs in fertility treatment may modify the risk of ovarian cancer among subgroups of women. However, although this study is by far the largest to date, additional large epidemiological studies with longer follow-up time are needed to further clarify the observed associations.
Trial registration number
Not applicable.
Collapse
Affiliation(s)
- A Jensen
- Danish Cancer Society Research Center, Lifestyle- Reproduction and Cancer , Copenhagen O, Denmark
| | - S Guleria
- Danish Cancer Society Research Center, Lifestyle- Reproduction and Cancer , Copenhagen O, Denmark
| | - V Albieri
- Danish Cancer Society Research Center, Statistics and Data Analysis , Copenhagen O, Denmark
| | - B Nøhr
- University Hospital of Herlev and Gentofte, Department of Obstetrics and Gynecology , Herlev, Denmark
| | - K Frederiksen
- Danish Cancer Society Research Center, Statistics and Data Analysis , Copenhagen O, Denmark
| | - S.K Kjær
- Danish Cancer Society Research Center, Virus- Lifestyle and Genes , Copenhagen O, Denmark
- University of Copenhagen, Department of Gynecology- Rigshospitalet , Copenhagen O, Denmark
| |
Collapse
|
20
|
Lee AW, Phung MT, Jensen A, Wu AH, Cramer DW, Modugno F, Harris H, Doherty JA, Schildkraut J, Terry KL, Moysich KB, Pike MC, Goodman MT, Webb PM, Kjaer SK, Pearce CL. Abstract 736: Exploring the impact of infertility and its treatments on risk of ovarian cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Infertility is related to both nulligravidity and endometriosis, which are both well-established risk factors for ovarian cancer. Infertility is also characterized by various underlying causes and can be treated with different types of fertility drugs. However, most studies to date have been unable to properly address these important issues when examining the infertility-ovarian cancer association due to small numbers of patients and a lack of detailed infertility and risk factor information.
Methods: We pooled self-reported data from 8,324 invasive, epithelial ovarian cancer cases and 13,325 control women in eight population-based case-control studies participating in the Ovarian Cancer Association Consortium (OCAC) to study the infertility-ovarian cancer relationship. Women classified as having a history of infertility were those who had spoken to a doctor about infertility problems or those who had regular sexual intercourse without birth control for a prolonged period (usually one year) without getting pregnant. Cause of infertility as well as use of fertility drugs was examined among those who experienced infertility issues. These associations with risk of ovarian cancer were evaluated using logistic regression models and quantified using odds ratios (ORs) and 95% confidence intervals (CIs). Gravidity and endometriosis were considered in the analyses as well as potential confounding factors.
Results: Overall, infertility was not associated with risk of ovarian cancer (OR=1.02, 95% CI 0.95-1.09). However, women who reported their infertility was due to problems with ovulation or menstruation showed a decreased risk (OR=0.72, 95% CI 0.52-1.01 and OR=0.62, 95% CI 0.43-0.91, respectively) whereas women who reported their infertility was due to endometriosis were at an increased risk (OR=1.54, 95% CI 1.19-1.98). Among women who reported infertility issues, use of fertility drugs was not associated with an increased risk of ovarian cancer regardless of their gravidity status (OR=0.89, 95% CI 0.76-1.05).
Conclusions: The relationship between infertility and risk of ovarian cancer is complex. Although infertility does not appear to be an independent risk factor for ovarian cancer, specific causes of infertility may be differentially associated with ovarian cancer risk, which may shed light on the disease’s underlying etiology. In addition, for women experiencing infertility issues, use of fertility drugs did not show an increased risk of ovarian cancer, which may have important clinical implications.
Citation Format: Alice W. Lee, Minh T. Phung, Allan Jensen, Anna H. Wu, Daniel W. Cramer, Francesmary Modugno, Holly Harris, Jennifer A. Doherty, Joellen Schildkraut, Kathryn L. Terry, Kirsten B. Moysich, Malcolm C. Pike, Marc T. Goodman, Penelope M. Webb, Susanne K. Kjaer, Celeste L. Pearce. Exploring the impact of infertility and its treatments on risk of ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 736.
Collapse
Affiliation(s)
- Alice W. Lee
- 1California State University, Fullerton, Fullerton, CA
| | - Minh T. Phung
- 2University of Michigan School of Public Health, Ann Arbor, MI
| | - Allan Jensen
- 3Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Anna H. Wu
- 4University of Southern California Keck School of Medicine, Los Angeles, CA
| | | | | | - Holly Harris
- 7Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | | | | | | | | | | | - Penelope M. Webb
- 13QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | | | | |
Collapse
|
21
|
Wuensche T, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman E, Janssen B, Windhorst A, Christensen S, Jensen A, Asuni A, Bang-Andersen B, Beaino W, van Dongen G, Vugts D. Development of 89Zr-antibody-PET imaging to evaluate improved brain targeting via transferrin receptor 1: the chelator matters. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00092-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Lautenschlaeger FS, Dumke R, Schymalla M, Hauswald H, Carl B, Stein M, Keber U, Jensen A, Engenhart-Cabillic R, Eberle F. Comparison of carbon ion and photon reirradiation for recurrent glioblastoma. Strahlenther Onkol 2022; 198:427-435. [PMID: 34523017 PMCID: PMC9038837 DOI: 10.1007/s00066-021-01844-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 07/25/2021] [Indexed: 12/03/2022]
Abstract
PURPOSE Purpose of this study was to investigate overall survival in recurrent glioblastoma treated with either carbon ion reirradiation or photon reirradiation. MATERIALS AND METHODS In this retrospective study we evaluated 78 consecutive patients with recurrent IDH (Isocitrate dehydrogenase)-wildtype glioblastoma (38 patients carbon ion re-radiotherapy, 40 patients photon re-radiotherapy) treated with either carbon ion reirradiation or stereotactic photon reirradiation. 45 Gy (RBE; 15 fractions) carbon ion reirradiation (CIRT) or 39 Gy (13 fractions) photon reirradiation (FSRT) was administered, respectively. Overall survival was investigated with respect to histological, clinical, and epidemiological features. Kaplan-Meier and multivariate Cox statistics were calculated. A propensity score-matched analysis of the FSRT and CIRT groups using variables from a validated prognosis score was carried out. RESULTS The type of reirradiation (CIRT vs. FSRT) significantly influenced overall survival-8.0 months vs. 6.5 months (univariate: p = 0.046)-and remained an independent prognostic factor in multivariate analysis (p = 0.017). Propensity score-adjusted analysis with CIRT versus FSRT as the dependent variable yielded a significant overall survival advantage for the CIRT group (median OS 8.9 versus 7.2 months, p = 0.041, 1‑year survival 29 versus 10%). Adverse events (AE) were evaluated for both subgroups. For the FSRT group no toxicity ≥ grade 4 occurred. For the CIRT subgroup no grade 5 AE occurred, but 1 patient developed a grade 4 radionecrosis. We encountered 4 grade 3 toxicities. One patient developed a zoster at the trunk, 2 progressed in their paresis, and 1 featured progressive dysesthesia. CONCLUSION In conclusion, carbon ion treatment is a safe and feasible treatment option for recurrent glioblastoma. Due to the retrospective nature of the study and two different dose levels for CIRT or FSRT, the improved outcome in CIRT reirradiation might be an effect of higher biological impact from carbon ions or a simple dose-escalation effect. This hypothesis needs prospective testing in larger patient cohorts. A prospective phase III randomized trial is in preparation at our center.
Collapse
Affiliation(s)
- F S Lautenschlaeger
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany.
- Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany.
| | - R Dumke
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
| | - M Schymalla
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
| | - H Hauswald
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
- Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany
- RNS Gemeinschaftspraxis, St. Josefs-Hospital, Wiesbaden, Germany
- Klinik für Radio-Onkologie, Universitätsklinikum Heidelberg, Heidelberg, Germany
| | - B Carl
- Klinik für Neurochirurgie, Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
- Klinik für Neurochirurgie, Universitätsklinikum Marburg, Marburg, Germany
| | - M Stein
- Klinik für Neurochirurgie, Universitätsklinikum Gießen, Gießen, Germany
| | - U Keber
- Institut für Neuropathologie, Universitätsklinikum Marburg, Marburg, Germany
| | - A Jensen
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
- Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Gießen, Gießen, Germany
| | - R Engenhart-Cabillic
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
- Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Gießen, Gießen, Germany
| | - F Eberle
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Marburg, Marburg, Germany
- Marburg Ion-Beam Therapy Center (MIT), Marburg, Germany
| |
Collapse
|
23
|
Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 2022; 30:630-631. [PMID: 35314806 PMCID: PMC9090804 DOI: 10.1038/s41431-022-01085-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Eileen O Dareng
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Jonathan P Tyrer
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
| | - Daniel R Barnes
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Michelle R Jones
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Xin Yang
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Katja K H Aben
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
- Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Muriel A Adank
- The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands
| | - Simona Agata
- Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy
| | - Irene L Andrulis
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada
- University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada
| | - Hoda Anton-Culver
- University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA
| | - Natalia N Antonenkova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
| | | | - Banu K Arun
- University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX, USA
| | - Annelie Augustinsson
- Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
| | - Judith Balmaña
- Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain
- University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain
| | - Elisa V Bandera
- Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New Brunswick, NJ, USA
| | - Rosa B Barkardottir
- Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland
- University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland
| | - Daniel Barrowdale
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Matthias W Beckmann
- University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
| | - Alicia Beeghly-Fadiel
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Javier Benitez
- Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
| | - Marina Bermisheva
- Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia
| | - Marcus Q Bernardini
- Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada
| | - Line Bjorge
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Amanda Black
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Natalia V Bogdanova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
- Hannover Medical School, Department of Radiation Oncology, Hannover, Germany
- Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
| | - Bernardo Bonanni
- IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, Italy
| | - Ake Borg
- Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden
| | - James D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Agnieszka Budzilowska
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland
| | - Ralf Butzow
- University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - Saundra S Buys
- Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA
| | - Hui Cai
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Maria A Caligo
- University Hospital, SOD Genetica Molecolare, Pisa, Italy
| | - Ian Campbell
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
- The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia
| | - Rikki Cannioto
- Roswell Park Cancer Institute, Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Buffalo, NY, USA
| | - Hayley Cassingham
- Division of Human Genetics, The Ohio State University, Department of Internal Medicine, Columbus, OH, USA
| | - Jenny Chang-Claude
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
- University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany
| | - Stephen J Chanock
- National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Kexin Chen
- Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China
| | - Yoke-Eng Chiew
- The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia
| | - Wendy K Chung
- Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA
| | | | - Sarah Colonna
- Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA
| | - Linda S Cook
- University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
- Alberta Health Services, Department of Cancer Epidemiology and Prevention Research, Calgary, AB, Canada
| | - Fergus J Couch
- Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA
| | - Mary B Daly
- Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA
| | - Fanny Dao
- Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New York, NY, USA
| | | | - Miguel de la Hoya
- CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain
| | - Robin de Putter
- Ghent University, Centre for Medical Genetics, Gent, Belgium
| | - Joe Dennis
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Allison DePersia
- NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA
- The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - Peter Devilee
- Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands
| | - Orland Diez
- Vall dHebron Institute of Oncology (VHIO), Oncogenetics Group, Barcelona, Spain
- University Hospital Vall dHebron, Clinical and Molecular Genetics Area, Barcelona, Spain
| | - Yuan Chun Ding
- Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
| | - Jennifer A Doherty
- University of Utah, Huntsman Cancer Institute, Department of Population Health Sciences, Salt Lake City, UT, USA
| | - Susan M Domchek
- University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, Philadelphia, PA, USA
| | - Thilo Dörk
- Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
| | - Andreas du Bois
- Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology, Essen, Germany
- Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
| | - Matthias Dürst
- Jena University Hospital-Friedrich Schiller University, Department of Gynaecology, Jena, Germany
| | - Diana M Eccles
- University of Southampton, Faculty of Medicine, Southampton, UK
| | - Heather A Eliassen
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA, USA
| | - Christoph Engel
- University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany
- University of Leipzig, LIFE-Leipzig Research Centre for Civilization Diseases, Leipzig, Germany
| | - Gareth D Evans
- University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK
- St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, UK
| | - Peter A Fasching
- University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
- University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA
| | - James M Flanagan
- Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, London, UK
| | - Renée T Fortner
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
| | - Eva Machackova
- Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics, Brno, Czech Republic
| | - Eitan Friedman
- Chaim Sheba Medical Center, The Susanne Levy Gertner Oncogenetics Unit, Ramat Gan, Israel
- Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel
| | - Patricia A Ganz
- Jonsson Comprehensive Cancer Centre, UCLA, Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Los Angeles, CA, USA
| | - Judy Garber
- Dana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA, USA
| | - Francesca Gensini
- University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, Florence, Italy
| | - Graham G Giles
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
| | - Gord Glendon
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada
| | - Andrew K Godwin
- University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, USA
| | - Marc T Goodman
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA
| | - Mark H Greene
- National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Jacek Gronwald
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
| | - Eric Hahnen
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
| | - Christopher A Haiman
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Niclas Håkansson
- Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
| | - Ute Hamann
- German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
| | - Thomas V O Hansen
- Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, Copenhagen, Denmark
| | - Holly R Harris
- Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, WA, USA
- University of Washington, Department of Epidemiology, Seattle, WA, USA
| | - Mikael Hartman
- National University of Singapore and National University Health System, Saw Swee Hock School of Public Health, Singapore, Singapore
- National University Health System, Department of Surgery, Singapore, Singapore
| | - Florian Heitz
- Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology, Essen, Germany
- Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
- Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Berlin, Germany
| | | | - Estrid Høgdall
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
- University of Copenhagen, Molecular Unit, Department of Pathology, Herlev Hospital, Copenhagen, Denmark
| | - Claus K Høgdall
- University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark
| | - John L Hopper
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
| | - Ruea-Yea Huang
- Roswell Park Cancer Institute, Center For Immunotherapy, Buffalo, NY, USA
| | - Chad Huff
- University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston, TX, USA
| | - Peter J Hulick
- NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA
- The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - David G Huntsman
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver, BC, Canada
- University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
- University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, BC, Canada
- BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, BC, Canada
| | | | - Claudine Isaacs
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
| | - Anna Jakubowska
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
- Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic Diagnostics, Szczecin, Poland
| | - Paul A James
- The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia
- Peter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, VIC, Australia
| | - Ramunas Janavicius
- Vilnius University Hospital Santariskiu Clinics, Hematology, oncology and transfusion medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius, Lithuania
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
| | - Allan Jensen
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
| | | | - Esther M John
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
| | - Michael E Jones
- The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
| | - Daehee Kang
- Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, Korea
- Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea
- Seoul National University, Cancer Research Institute, Seoul, Korea
| | - Beth Y Karlan
- University of California at Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Anthony Karnezis
- UC Davis Medical Center, Department of Pathology and Laboratory Medicine, Sacramento, CA, USA
| | - Linda E Kelemen
- Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
| | - Elza Khusnutdinova
- Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia
- Saint Petersburg State University, Saint Petersburg, Russia
| | - Lambertus A Kiemeney
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Byoung-Gie Kim
- Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea
| | - Susanne K Kjaer
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
- University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark
| | - Ian Komenaka
- City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA
| | - Jolanta Kupryjanczyk
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland
| | - Allison W Kurian
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
| | - Ava Kwong
- Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong
- The University of Hong Kong, Department of Surgery, Pok Fu Lam, Hong Kong
- Hong Kong Sanatorium and Hospital, Department of Surgery, Happy Valley, Hong Kong
| | - Diether Lambrechts
- VIB Center for Cancer Biology, Leuven, Belgium
- University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium
| | - Melissa C Larson
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Conxi Lazaro
- ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Hereditary Cancer Program, Barcelona, Spain
| | - Nhu D Le
- BC Cancer, Cancer Control Research, Vancouver, BC, Canada
| | - Goska Leslie
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Jenny Lester
- University of California at Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Fabienne Lesueur
- Institut Curie, Paris, France
- Mines ParisTech, Fontainebleau, France
- Inserm U900, Genetic Epidemiology of Cancer team, Paris, France
| | - Douglas A Levine
- Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New York, NY, USA
- NYU Langone Medical Center, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York, NY, USA
| | - Lian Li
- Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China
| | - Jingmei Li
- Genome Institute of Singapore, Human Genetics Division, Singapore, Singapore
| | - Jennifer T Loud
- National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Karen H Lu
- University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Clinical Cancer Genetics Program, Houston, TX, USA
| | - Jan Lubiński
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
| | - Phuong L Mai
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Siranoush Manoukian
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Unit of Medical Genetics, Department of Medical Oncology and Hematology, Milan, Italy
| | - Jeffrey R Marks
- Duke University Hospital, Department of Surgery, Durham, NC, USA
| | - Rayna Kim Matsuno
- University of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, HI, USA
| | - Keitaro Matsuo
- Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, Nagoya, Japan
- Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, Japan
| | - Taymaa May
- Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada
| | - Lesley McGuffog
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - John R McLaughlin
- Samuel Lunenfeld Research Institute, Public Health Ontario, Toronto, ON, Canada
| | - Iain A McNeish
- Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, UK
- University of Glasgow, Institute of Cancer Sciences, Glasgow, UK
| | - Noura Mebirouk
- Institut Curie, Paris, France
- Mines ParisTech, Fontainebleau, France
- Inserm U900, Genetic Epidemiology of Cancer team, Paris, France
| | - Usha Menon
- University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK
| | - Austin Miller
- Roswell Park Cancer Institute, NRG Oncology, Statistics and Data Management Center, Buffalo, NY, USA
| | - Roger L Milne
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
| | - Albina Minlikeeva
- Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA
| | - Francesmary Modugno
- Magee-Womens Research Institute and Hillman Cancer Center, Womens Cancer Research Center, Pittsburgh, PA, USA
- University of Pittsburgh School of Medicine, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA, USA
| | - Marco Montagna
- Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy
| | - Kirsten B Moysich
- Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA
| | - Elizabeth Munro
- Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA
- Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA
| | - Katherine L Nathanson
- University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, Philadelphia, PA, USA
| | - Susan L Neuhausen
- Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
| | - Heli Nevanlinna
- University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland
| | - Joanne Ngeow Yuen Yie
- National Cancer Centre, Cancer Genetics Service, Singapore, Singapore
- Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore
| | | | - Finn C Nielsen
- Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, Copenhagen, Denmark
| | | | - Kunle Odunsi
- Roswell Park Cancer Institute, Department of Gynecologic Oncology, Buffalo, NY, USA
| | - Kenneth Offit
- Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, New York, NY, USA
- Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, New York, NY, USA
| | - Edith Olah
- National Institute of Oncology, Department of Molecular Genetics, Budapest, Hungary
| | - Siel Olbrecht
- University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, Leuven, Belgium
| | | | - Sara H Olson
- Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA
| | - Håkan Olsson
- Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
| | - Ana Osorio
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Laura Papi
- University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, Florence, Italy
| | - Sue K Park
- Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, Korea
- Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea
- Seoul National University, Cancer Research Institute, Seoul, Korea
| | - Michael T Parsons
- QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD, Australia
| | - Harsha Pathak
- University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, USA
| | - Inge Sokilde Pedersen
- Aalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark
- Aalborg University Hospital, Clinical Cancer Research Center, Aalborg, Denmark
- Aalborg University, Department of Clinical Medicine, Aalborg, Denmark
| | - Ana Peixoto
- Portuguese Oncology Institute, Department of Genetics, Porto, Portugal
| | - Tanja Pejovic
- Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA
- Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA
| | - Pedro Perez-Segura
- CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain
| | - Jennifer B Permuth
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Beth Peshkin
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
| | - Paolo Peterlongo
- IFOM-the FIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan, Italy
| | - Anna Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Darya Prokofyeva
- Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia
| | - Paolo Radice
- Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, Italy
| | | | - Marjorie J Riggan
- Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA
| | - Harvey A Risch
- Yale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, USA
| | - Cristina Rodriguez-Antona
- Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
| | - Eric Ross
- Fox Chase Cancer Center, Population Studies Facility, Philadelphia, PA, USA
| | - Mary Anne Rossing
- Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, WA, USA
- University of Washington, Department of Epidemiology, Seattle, WA, USA
| | - Ingo Runnebaum
- Jena University Hospital-Friedrich Schiller University, Department of Gynaecology, Jena, Germany
| | - Dale P Sandler
- National Institute of Environmental Health Sciences, NIH, Epidemiology Branch, Research Triangle Park, NC, USA
| | - Marta Santamariña
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
| | - Penny Soucy
- Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Genomics Center, Québec City, QC, Canada
| | - Rita K Schmutzler
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - V Wendy Setiawan
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Kang Shan
- Hebei Medical University, Fourth Hospital, Department of Obstetrics and Gynaecology, Shijiazhuang, China
| | - Weiva Sieh
- Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, New York, NY, USA
- Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, NY, USA
| | - Jacques Simard
- Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Genomic Center, Québec City, QC, Canada
| | - Christian F Singer
- Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria
| | | | - Honglin Song
- University of Cambridge, Department of Public Health and Primary Care, Cambridge, UK
| | - Melissa C Southey
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
- The University of Melbourne, Department of Clinical Pathology, Melbourne, VIC, Australia
| | - Helen Steed
- Royal Alexandra Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Edmonton, AB, Canada
| | - Dominique Stoppa-Lyonnet
- INSERM U830, Department of Tumour Biology, Paris, France
- Institut Curie, Service de Génétique, Paris, France
- Université Paris Descartes, Paris, France
| | - Rebecca Sutphen
- University of South Florida, Epidemiology Center, College of Medicine, Tampa, FL, USA
| | - Anthony J Swerdlow
- The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
- The Institute of Cancer Research, Division of Breast Cancer Research, London, UK
| | - Yen Yen Tan
- Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria
| | - Manuel R Teixeira
- Portuguese Oncology Institute, Department of Genetics, Porto, Portugal
- University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal
| | - Soo Hwang Teo
- Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, Malaysia
- University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, Malaysia
| | - Kathryn L Terry
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Brigham and Women's Hospital and Harvard Medical School, Obstetrics and Gynecology Epidemiology Center, Boston, MA, USA
| | - Mary Beth Terry
- Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA
| | - Mads Thomassen
- Odense University Hospital, Department of Clinical Genetics, Odence C, Denmark
| | - Pamela J Thompson
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA
| | - Liv Cecilie Vestrheim Thomsen
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Darcy L Thull
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh, PA, USA
| | - Marc Tischkowitz
- McGill University, Program in Cancer Genetics, Departments of Human Genetics and Oncology, Montréal, QC, Canada
- University of Cambridge, Department of Medical Genetics, Cambridge, UK
| | - Linda Titus
- Dartmouth College, Geisel School of Medicine, Hanover, NH, USA
| | - Amanda E Toland
- The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH, USA
| | - Diana Torres
- German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
- Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia
| | - Britton Trabert
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Ruth Travis
- University of Oxford, Cancer Epidemiology Unit, Oxford, UK
| | - Nadine Tung
- Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA, USA
| | - Shelley S Tworoger
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Ellen Valen
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Anne M van Altena
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Annemieke H van der Hout
- University Medical Center Groningen, University Groningen, Department of Genetics, Groningen, The Netherlands
| | - Els Van Nieuwenhuysen
- University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, Leuven, Belgium
| | | | - Ana Vega
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - Digna Velez Edwards
- Vanderbilt University Medical Center, Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Nashville, TN, USA
| | - Robert A Vierkant
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Frances Wang
- Duke Cancer Institute, Cancer Control and Population Sciences, Durham, NC, USA
- Duke University Hospital, Department of Community and Family Medicine, Durham, NC, USA
| | - Barbara Wappenschmidt
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
| | - Penelope M Webb
- QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, QLD, Australia
| | - Clarice R Weinberg
- National Institute of Environmental Health Sciences, NIH, Biostatistics and Computational Biology Branch, Research Triangle Park, NC, USA
| | | | - Nicolas Wentzensen
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Emily White
- University of Washington, Department of Epidemiology, Seattle, WA, USA
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Alice S Whittemore
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA
| | - Stacey J Winham
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Alicja Wolk
- Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
- Uppsala University, Department of Surgical Sciences, Uppsala, Sweden
| | - Yin-Ling Woo
- University of Malaya, Department of Obstetrics and Gynaecology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
| | - Anna H Wu
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Li Yan
- Hebei Medical University, Fourth Hospital, Department of Molecular Biology, Shijiazhuang, China
| | - Drakoulis Yannoukakos
- National Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory, INRASTES, Athens, Greece
| | | | - Wei Zheng
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Argyrios Ziogas
- University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA
| | - Kristin K Zorn
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Zdenek Kleibl
- Institute of Biochemistry and Experimental Oncology, First Faculty od Medicine, Charles University, Prague, Czech Republic
| | - Douglas Easton
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
| | - Kate Lawrenson
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Anna DeFazio
- The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia
| | | | - Susan J Ramus
- University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, NSW, Australia
- University of NSW Sydney, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, NSW, Australia
| | - Celeste L Pearce
- University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI, USA
- University of Southern California Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Alvaro N Monteiro
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Julie Cunningham
- Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, MN, USA
| | - Ellen L Goode
- Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, MN, USA
| | - Joellen M Schildkraut
- Emory University, Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA
| | - Andrew Berchuck
- Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA
| | - Georgia Chenevix-Trench
- QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD, Australia
| | - Simon A Gayther
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Antonis C Antoniou
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Paul D P Pharoah
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK.
| |
Collapse
|
24
|
Everhøj C, Norsker FN, Rechnitzer C, Licht SDF, Nielsen TT, Kjær SK, Jensen A, Hargreave M, Christensen J, Belmonte F, Urhoj SK, Strandberg-Larsen K, Winther JF, Kenborg L. Effects of early maternal cancer and fertility treatment on the risk of adverse birth outcomes. EClinicalMedicine 2022; 46:101369. [PMID: 35399810 PMCID: PMC8987408 DOI: 10.1016/j.eclinm.2022.101369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Early maternal cancer and fertility treatment each increase the risk for adverse birth outcomes, but the joint effect of these outcomes has not yet been reported. Thus, the aim was to assess the individual and joint effect of maternal cancer and fertility treatment on the risk for adverse birth outcomes. METHODS This population-based cohort study included 5487 live-born singletons identified in the Danish Medical Birth Register (1994-2016) of mothers with previous cancer (<40 years) recorded in the Danish Cancer Registry (1955-2014). We randomly selected 80,262 live-born singletons of mothers with no cancer <40 years matched to mothers with cancer by birth year and month. We calculated odds ratios (ORs) for preterm birth, low birth weight (LBW) (<2500 g) and small for gestational age (SGA), mean differences in birth weight in grams, and additional cases of preterm birth (gestational age<259 days) per 100,000 person-years. Multiplicative and additive interaction of maternal cancer and fertility treatment was compared with outcomes of children conceived naturally to mothers with no maternal cancer (reference group). FINDINGS Among 84,332 live-born singletons, increased ORs for preterm birth were observed among children born to mothers with previous cancer (1·48, 95% confidence interval [CI] 1·33-1.65) or after fertility treatment (1·43, 95% 1·28-1-61), with 22 additional cases of preterm birth among both group of children (95% CI 15-29; 95% CI 14-30). In the joint analyses, the OR for SGA for children born after fertility treatment to mothers with previous cancer was similar to that of the reference group (OR 1·02, 95% CI 0·72-1·44, P for interaction=0·52). Children with both exposures had increased ORs for LBW (1·86, 95% CI 1·17-2·96, P for interaction=0·06) and preterm birth (2·31, 955 CI 1·66-3·20, P for interaction = 0·56), with 61 additional cases of preterm birth (95% CI 27-95, P for interaction=0.26) over that of children in the reference group. The mean birth weight was also lower in children born to mothers with both exposures (-140 g, 95% CI -215; -65) (P for interaction=0.06) but decreased to -22 g (95% CI -76; 31) after adjustment for GA. INTERPRETATION Although we did not find any statistically significant additive interaction between maternal cancer and fertility treatment, children born after fertility treatment of mothers with previous cancer were at increased risk for adverse birth outcomes. Thus, pregnant women with both exposures need close follow-up during pregnancy. FUNDING The Danish Cancer Society and the Danish Childhood Cancer Foundation.
Collapse
Affiliation(s)
- Cathrine Everhøj
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
| | - Filippa Nyboe Norsker
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
| | - Catherine Rechnitzer
- Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Sofie de Fine Licht
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
| | - Thomas T Nielsen
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
| | - Susanne K. Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Marie Hargreave
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Jane Christensen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Federica Belmonte
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Stine Kjaer Urhoj
- Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark
| | | | - Jeanette F Winther
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
- Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
| | - Line Kenborg
- Childhood Cancer Research Group, Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark
- Corresponding author.
| |
Collapse
|
25
|
Jensen A. Arts on prescription (AoP) in primary healthcare in Sweden. Perspect Public Health 2022; 142:64-65. [PMID: 35274561 DOI: 10.1177/17579139211072772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- A Jensen
- Arts & Health Strategist, Primary Healthcare, Region Skåne, Sweden
| |
Collapse
|
26
|
Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 2022; 30:349-362. [PMID: 35027648 PMCID: PMC8904525 DOI: 10.1038/s41431-021-00987-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 08/09/2021] [Accepted: 09/27/2021] [Indexed: 12/14/2022] Open
Abstract
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
Collapse
Affiliation(s)
- Eileen O Dareng
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Jonathan P Tyrer
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
| | - Daniel R Barnes
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Michelle R Jones
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Xin Yang
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Katja K H Aben
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
- Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Muriel A Adank
- The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands
| | - Simona Agata
- Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy
| | - Irene L Andrulis
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada
- University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada
| | - Hoda Anton-Culver
- University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA
| | - Natalia N Antonenkova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
| | | | - Banu K Arun
- University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX, USA
| | - Annelie Augustinsson
- Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
| | - Judith Balmaña
- Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain
- University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain
| | - Elisa V Bandera
- Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New Brunswick, NJ, USA
| | - Rosa B Barkardottir
- Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland
- University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland
| | - Daniel Barrowdale
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Matthias W Beckmann
- University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
| | - Alicia Beeghly-Fadiel
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Javier Benitez
- Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
| | - Marina Bermisheva
- Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia
| | - Marcus Q Bernardini
- Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada
| | - Line Bjorge
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Amanda Black
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Natalia V Bogdanova
- N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
- Hannover Medical School, Department of Radiation Oncology, Hannover, Germany
- Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
| | - Bernardo Bonanni
- IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, Italy
| | - Ake Borg
- Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden
| | - James D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Agnieszka Budzilowska
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland
| | - Ralf Butzow
- University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - Saundra S Buys
- Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA
| | - Hui Cai
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Maria A Caligo
- University Hospital, SOD Genetica Molecolare, Pisa, Italy
| | - Ian Campbell
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
- The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia
| | - Rikki Cannioto
- Roswell Park Cancer Institute, Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Buffalo, NY, USA
| | - Hayley Cassingham
- Division of Human Genetics, The Ohio State University, Department of Internal Medicine, Columbus, OH, USA
| | - Jenny Chang-Claude
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
- University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany
| | - Stephen J Chanock
- National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Kexin Chen
- Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China
| | - Yoke-Eng Chiew
- The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia
| | - Wendy K Chung
- Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA
| | | | - Sarah Colonna
- Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA
| | - Linda S Cook
- University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
- Alberta Health Services, Department of Cancer Epidemiology and Prevention Research, Calgary, AB, Canada
| | - Fergus J Couch
- Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA
| | - Mary B Daly
- Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA
| | - Fanny Dao
- Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New York, NY, USA
| | | | - Miguel de la Hoya
- CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain
| | - Robin de Putter
- Ghent University, Centre for Medical Genetics, Gent, Belgium
| | - Joe Dennis
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Allison DePersia
- NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA
- The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - Peter Devilee
- Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands
- Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands
| | - Orland Diez
- Vall dHebron Institute of Oncology (VHIO), Oncogenetics Group, Barcelona, Spain
- University Hospital Vall dHebron, Clinical and Molecular Genetics Area, Barcelona, Spain
| | - Yuan Chun Ding
- Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
| | - Jennifer A Doherty
- University of Utah, Huntsman Cancer Institute, Department of Population Health Sciences, Salt Lake City, UT, USA
| | - Susan M Domchek
- University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, Philadelphia, PA, USA
| | - Thilo Dörk
- Hannover Medical School, Gynaecology Research Unit, Hannover, Germany
| | - Andreas du Bois
- Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology, Essen, Germany
- Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
| | - Matthias Dürst
- Jena University Hospital-Friedrich Schiller University, Department of Gynaecology, Jena, Germany
| | - Diana M Eccles
- University of Southampton, Faculty of Medicine, Southampton, UK
| | - Heather A Eliassen
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA, USA
| | - Christoph Engel
- University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany
- University of Leipzig, LIFE-Leipzig Research Centre for Civilization Diseases, Leipzig, Germany
| | - Gareth D Evans
- University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK
- St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, UK
| | - Peter A Fasching
- University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany
- University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA
| | - James M Flanagan
- Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, London, UK
| | - Renée T Fortner
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
| | - Eva Machackova
- Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics, Brno, Czech Republic
| | - Eitan Friedman
- Chaim Sheba Medical Center, The Susanne Levy Gertner Oncogenetics Unit, Ramat Gan, Israel
- Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel
| | - Patricia A Ganz
- Jonsson Comprehensive Cancer Centre, UCLA, Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Los Angeles, CA, USA
| | - Judy Garber
- Dana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA, USA
| | - Francesca Gensini
- University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, Florence, Italy
| | - Graham G Giles
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
| | - Gord Glendon
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada
| | - Andrew K Godwin
- University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, USA
| | - Marc T Goodman
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA
| | - Mark H Greene
- National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Jacek Gronwald
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
| | - Eric Hahnen
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
| | - Christopher A Haiman
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Niclas Håkansson
- Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
| | - Ute Hamann
- German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
| | - Thomas V O Hansen
- Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, Copenhagen, Denmark
| | - Holly R Harris
- Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, WA, USA
- University of Washington, Department of Epidemiology, Seattle, WA, USA
| | - Mikael Hartman
- National University of Singapore and National University Health System, Saw Swee Hock School of Public Health, Singapore, Singapore
- National University Health System, Department of Surgery, Singapore, Singapore
| | - Florian Heitz
- Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology, Essen, Germany
- Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
- Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Berlin, Germany
| | | | - Estrid Høgdall
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
- University of Copenhagen, Molecular Unit, Department of Pathology, Herlev Hospital, Copenhagen, Denmark
| | - Claus K Høgdall
- University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark
| | - John L Hopper
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
| | - Ruea-Yea Huang
- Roswell Park Cancer Institute, Center For Immunotherapy, Buffalo, NY, USA
| | - Chad Huff
- University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston, TX, USA
| | - Peter J Hulick
- NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA
- The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| | - David G Huntsman
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver, BC, Canada
- University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
- University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, BC, Canada
- BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, BC, Canada
| | | | - Claudine Isaacs
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
| | - Anna Jakubowska
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
- Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic Diagnostics, Szczecin, Poland
| | - Paul A James
- The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia
- Peter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, VIC, Australia
| | - Ramunas Janavicius
- Vilnius University Hospital Santariskiu Clinics, Hematology, oncology and transfusion medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius, Lithuania
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
| | - Allan Jensen
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
| | | | - Esther M John
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
| | - Michael E Jones
- The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
| | - Daehee Kang
- Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, Korea
- Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea
- Seoul National University, Cancer Research Institute, Seoul, Korea
| | - Beth Y Karlan
- University of California at Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Anthony Karnezis
- UC Davis Medical Center, Department of Pathology and Laboratory Medicine, Sacramento, CA, USA
| | - Linda E Kelemen
- Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
| | - Elza Khusnutdinova
- Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia
- Saint Petersburg State University, Saint Petersburg, Russia
| | - Lambertus A Kiemeney
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Byoung-Gie Kim
- Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea
| | - Susanne K Kjaer
- Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark
- University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark
| | - Ian Komenaka
- City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA
| | - Jolanta Kupryjanczyk
- Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland
| | - Allison W Kurian
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
| | - Ava Kwong
- Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong
- The University of Hong Kong, Department of Surgery, Pok Fu Lam, Hong Kong
- Hong Kong Sanatorium and Hospital, Department of Surgery, Happy Valley, Hong Kong
| | - Diether Lambrechts
- VIB Center for Cancer Biology, Leuven, Belgium
- University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium
| | - Melissa C Larson
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Conxi Lazaro
- ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Hereditary Cancer Program, Barcelona, Spain
| | - Nhu D Le
- BC Cancer, Cancer Control Research, Vancouver, BC, Canada
| | - Goska Leslie
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Jenny Lester
- University of California at Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Fabienne Lesueur
- Institut Curie, Paris, France
- Mines ParisTech, Fontainebleau, France
- Inserm U900, Genetic Epidemiology of Cancer team, Paris, France
| | - Douglas A Levine
- Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New York, NY, USA
- NYU Langone Medical Center, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York, NY, USA
| | - Lian Li
- Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China
| | - Jingmei Li
- Genome Institute of Singapore, Human Genetics Division, Singapore, Singapore
| | - Jennifer T Loud
- National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Karen H Lu
- University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Clinical Cancer Genetics Program, Houston, TX, USA
| | - Jan Lubiński
- Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland
| | - Phuong L Mai
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Siranoush Manoukian
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Unit of Medical Genetics, Department of Medical Oncology and Hematology, Milan, Italy
| | - Jeffrey R Marks
- Duke University Hospital, Department of Surgery, Durham, NC, USA
| | - Rayna Kim Matsuno
- University of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, HI, USA
| | - Keitaro Matsuo
- Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, Nagoya, Japan
- Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, Japan
| | - Taymaa May
- Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada
| | - Lesley McGuffog
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - John R McLaughlin
- Samuel Lunenfeld Research Institute, Public Health Ontario, Toronto, ON, Canada
| | - Iain A McNeish
- Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, UK
- University of Glasgow, Institute of Cancer Sciences, Glasgow, UK
| | - Noura Mebirouk
- Institut Curie, Paris, France
- Mines ParisTech, Fontainebleau, France
- Inserm U900, Genetic Epidemiology of Cancer team, Paris, France
| | - Usha Menon
- University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK
| | - Austin Miller
- Roswell Park Cancer Institute, NRG Oncology, Statistics and Data Management Center, Buffalo, NY, USA
| | - Roger L Milne
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
| | - Albina Minlikeeva
- Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA
| | - Francesmary Modugno
- Magee-Womens Research Institute and Hillman Cancer Center, Womens Cancer Research Center, Pittsburgh, PA, USA
- University of Pittsburgh School of Medicine, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA, USA
| | - Marco Montagna
- Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy
| | - Kirsten B Moysich
- Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA
| | - Elizabeth Munro
- Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA
- Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA
| | - Katherine L Nathanson
- University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, Philadelphia, PA, USA
| | - Susan L Neuhausen
- Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA
| | - Heli Nevanlinna
- University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland
| | - Joanne Ngeow Yuen Yie
- National Cancer Centre, Cancer Genetics Service, Singapore, Singapore
- Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore
| | | | - Finn C Nielsen
- Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, Copenhagen, Denmark
| | | | - Kunle Odunsi
- Roswell Park Cancer Institute, Department of Gynecologic Oncology, Buffalo, NY, USA
| | - Kenneth Offit
- Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, New York, NY, USA
- Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, New York, NY, USA
| | - Edith Olah
- National Institute of Oncology, Department of Molecular Genetics, Budapest, Hungary
| | - Siel Olbrecht
- University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, Leuven, Belgium
| | | | - Sara H Olson
- Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA
| | - Håkan Olsson
- Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden
| | - Ana Osorio
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Laura Papi
- University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, Florence, Italy
| | - Sue K Park
- Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, Korea
- Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea
- Seoul National University, Cancer Research Institute, Seoul, Korea
| | - Michael T Parsons
- QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD, Australia
| | - Harsha Pathak
- University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, USA
| | - Inge Sokilde Pedersen
- Aalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark
- Aalborg University Hospital, Clinical Cancer Research Center, Aalborg, Denmark
- Aalborg University, Department of Clinical Medicine, Aalborg, Denmark
| | - Ana Peixoto
- Portuguese Oncology Institute, Department of Genetics, Porto, Portugal
| | - Tanja Pejovic
- Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA
- Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA
| | - Pedro Perez-Segura
- CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain
| | - Jennifer B Permuth
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Beth Peshkin
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
| | - Paolo Peterlongo
- IFOM-the FIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan, Italy
| | - Anna Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Darya Prokofyeva
- Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia
| | - Paolo Radice
- Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, Italy
| | | | - Marjorie J Riggan
- Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA
| | - Harvey A Risch
- Yale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, USA
| | - Cristina Rodriguez-Antona
- Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain
| | - Eric Ross
- Fox Chase Cancer Center, Population Studies Facility, Philadelphia, PA, USA
| | - Mary Anne Rossing
- Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, WA, USA
- University of Washington, Department of Epidemiology, Seattle, WA, USA
| | - Ingo Runnebaum
- Jena University Hospital-Friedrich Schiller University, Department of Gynaecology, Jena, Germany
| | - Dale P Sandler
- National Institute of Environmental Health Sciences, NIH, Epidemiology Branch, Research Triangle Park, NC, USA
| | - Marta Santamariña
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
| | - Penny Soucy
- Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Genomics Center, Québec City, QC, Canada
| | - Rita K Schmutzler
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - V Wendy Setiawan
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Kang Shan
- Hebei Medical University, Fourth Hospital, Department of Obstetrics and Gynaecology, Shijiazhuang, China
| | - Weiva Sieh
- Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, New York, NY, USA
- Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, NY, USA
| | - Jacques Simard
- Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Genomic Center, Québec City, QC, Canada
| | - Christian F Singer
- Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria
| | | | - Honglin Song
- University of Cambridge, Department of Public Health and Primary Care, Cambridge, UK
| | - Melissa C Southey
- Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia
- Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia
- The University of Melbourne, Department of Clinical Pathology, Melbourne, VIC, Australia
| | - Helen Steed
- Royal Alexandra Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Edmonton, AB, Canada
| | - Dominique Stoppa-Lyonnet
- INSERM U830, Department of Tumour Biology, Paris, France
- Institut Curie, Service de Génétique, Paris, France
- Université Paris Descartes, Paris, France
| | - Rebecca Sutphen
- University of South Florida, Epidemiology Center, College of Medicine, Tampa, FL, USA
| | - Anthony J Swerdlow
- The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK
- The Institute of Cancer Research, Division of Breast Cancer Research, London, UK
| | - Yen Yen Tan
- Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria
| | - Manuel R Teixeira
- Portuguese Oncology Institute, Department of Genetics, Porto, Portugal
- University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal
| | - Soo Hwang Teo
- Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, Malaysia
- University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, Malaysia
| | - Kathryn L Terry
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Brigham and Women's Hospital and Harvard Medical School, Obstetrics and Gynecology Epidemiology Center, Boston, MA, USA
| | - Mary Beth Terry
- Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA
| | - Mads Thomassen
- Odense University Hospital, Department of Clinical Genetics, Odence C, Denmark
| | - Pamela J Thompson
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA
| | - Liv Cecilie Vestrheim Thomsen
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Darcy L Thull
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh, PA, USA
| | - Marc Tischkowitz
- McGill University, Program in Cancer Genetics, Departments of Human Genetics and Oncology, Montréal, QC, Canada
- University of Cambridge, Department of Medical Genetics, Cambridge, UK
| | - Linda Titus
- Dartmouth College, Geisel School of Medicine, Hanover, NH, USA
| | - Amanda E Toland
- The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH, USA
| | - Diana Torres
- German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
- Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia
| | - Britton Trabert
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Ruth Travis
- University of Oxford, Cancer Epidemiology Unit, Oxford, UK
| | - Nadine Tung
- Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA, USA
| | - Shelley S Tworoger
- Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Ellen Valen
- Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway
| | - Anne M van Altena
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Annemieke H van der Hout
- University Medical Center Groningen, University Groningen, Department of Genetics, Groningen, The Netherlands
| | - Els Van Nieuwenhuysen
- University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, Leuven, Belgium
| | | | - Ana Vega
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - Digna Velez Edwards
- Vanderbilt University Medical Center, Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Nashville, TN, USA
| | - Robert A Vierkant
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Frances Wang
- Duke Cancer Institute, Cancer Control and Population Sciences, Durham, NC, USA
- Duke University Hospital, Department of Community and Family Medicine, Durham, NC, USA
| | - Barbara Wappenschmidt
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
| | - Penelope M Webb
- QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, QLD, Australia
| | - Clarice R Weinberg
- National Institute of Environmental Health Sciences, NIH, Biostatistics and Computational Biology Branch, Research Triangle Park, NC, USA
| | | | - Nicolas Wentzensen
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA
| | - Emily White
- University of Washington, Department of Epidemiology, Seattle, WA, USA
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Alice S Whittemore
- Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA
- Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA
| | - Stacey J Winham
- Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA
| | - Alicja Wolk
- Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
- Uppsala University, Department of Surgical Sciences, Uppsala, Sweden
| | - Yin-Ling Woo
- University of Malaya, Department of Obstetrics and Gynaecology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
| | - Anna H Wu
- University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Li Yan
- Hebei Medical University, Fourth Hospital, Department of Molecular Biology, Shijiazhuang, China
| | - Drakoulis Yannoukakos
- National Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory, INRASTES, Athens, Greece
| | | | - Wei Zheng
- Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Argyrios Ziogas
- University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA
| | - Kristin K Zorn
- Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Zdenek Kleibl
- Institute of Biochemistry and Experimental Oncology, First Faculty od Medicine, Charles University, Prague, Czech Republic
| | - Douglas Easton
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK
| | - Kate Lawrenson
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
| | - Anna DeFazio
- The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia
| | | | - Susan J Ramus
- University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, NSW, Australia
- University of NSW Sydney, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, NSW, Australia
| | - Celeste L Pearce
- University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI, USA
- University of Southern California Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA
| | - Alvaro N Monteiro
- Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA
| | - Julie Cunningham
- Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, MN, USA
| | - Ellen L Goode
- Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, MN, USA
| | - Joellen M Schildkraut
- Emory University, Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA
| | - Andrew Berchuck
- Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA
| | - Georgia Chenevix-Trench
- QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD, Australia
| | - Simon A Gayther
- Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Antonis C Antoniou
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK
| | - Paul D P Pharoah
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
- University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK.
| |
Collapse
|
27
|
Lindquist S, Kjær SK, Albieri V, Frederiksen K, Hansen T, Nøhr B, Jensen A. Fertility drugs and incidence of thyroid cancer in a Danish nationwide cohort of 146 024 infertile women. Hum Reprod 2022; 37:838-847. [PMID: 35020884 DOI: 10.1093/humrep/deab285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 12/13/2021] [Indexed: 12/24/2022] Open
Abstract
STUDY QUESTION Do fertility drugs increase the risk of thyroid cancer among infertile women? SUMMARY ANSWER The use of most types of fertility drugs was not associated with an increased risk of thyroid cancer. WHAT IS KNOWN ALREADY The incidence of thyroid cancer is higher for women than men, especially during reproductive years, indicating that reproductive hormones may be involved in the development of thyroid cancer. Only a few previous studies have examined the association between the use of fertility drugs and incidence of thyroid cancer and the results are inconclusive. STUDY DESIGN, SIZE, DURATION A retrospective, population-based cohort study including all 146 024 infertile women aged 20-45 years and living in Denmark in the period 1995-2017. The women were followed from the date of entry in the cohort (i.e. date of first infertility diagnosis) until the occurrence of thyroid cancer or any other cancer (except non-melanoma skin cancer), death, emigration, total thyroidectomy or the end of follow-up (31 December 2018), whichever occurred first. The median length of follow-up was 11.3 years. PARTICIPANTS/MATERIALS, SETTING, METHODS In total, 167 women were diagnosed with thyroid cancer during the follow-up period. Information on the use of specific fertility drugs (clomiphene citrate, gonadotropins, hCGs, GnRH receptor modulators and progesterone), thyroid cancer, covariates and vital status was obtained from the Danish Infertility Cohort and various Danish national registers. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% CIs for thyroid cancer overall and for papillary thyroid cancer. MAIN RESULTS AND THE ROLE OF CHANCE After adjustment for the calendar year of infertility diagnosis, the highest obtained level of education, parity status, obesity or thyroid disease and mutual adjustment for other registered fertility drugs, no marked associations were observed between the use of clomiphene citrate, hCG, gonadotropins or GnRH receptor modulators and risk of overall or papillary thyroid cancer. However, ever use of progesterone was associated with an increased rate of both overall (HR 1.63; 95% CI 1.07-2.48) and papillary (HR 1.66, 95% CI 1.04-2.65) thyroid cancer after mutual adjustment for other specific fertility drugs. For most specific fertility drugs, we observed a tendency toward higher associations with thyroid cancer within the first 5 years after the start of drug use than after 5 years from the start of use. No marked associations were detected according to the cumulative dose for any of the specific fertility drugs. LIMITATIONS, REASONS FOR CAUTION Despite a large study population, the statistical precision in some subgroup analyses may be affected due to the low number of thyroid cancer cases. Although we were able to adjust for a number of potential confounders, residual and unmeasured confounding may potentially have affected the observed associations, as we could not adjust for some factors that may influence the association between fertility drugs and thyroid cancer, including age at menarche and BMI. WIDER IMPLICATIONS OF THE FINDINGS Although this study, which is the largest to date, provides reassuring evidence that there is no strong link between the use of fertility drugs and thyroid cancer incidence, we observed a modest increased thyroid cancer incidence after the use of progesterone. However, we cannot rule out that this is a chance finding and the potential association between the use of progesterone and thyroid cancer should therefore be investigated further in large epidemiological studies. The results of the present study provide valuable knowledge for clinicians and other health care personnel involved in the diagnosis and treatment of infertility. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by research grants from the Jascha Foundation and the Aase and Ejner Danielsens Foundation. B.N. received honoraria and/or non-financial support by Gedeon Richter Nordics AB, IBSA Nordic APS and Merck KGAA. The remaining authors have no competing interests. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- Sofie Lindquist
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.,Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Vanna Albieri
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kirsten Frederiksen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Tatiana Hansen
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Bugge Nøhr
- The Fertility Clinic, Department of Obstetrics and Gynecology, Copenhagen University Hospital Herlev, Herlev, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| |
Collapse
|
28
|
Stergiou N, Wünsche T, Mes I, Schreurs M, Verlaan M, Kooijman E, Windhorst AD, Dongen GAMS, Helboe L, Vergo S, Christensen S, Asuni AA, Jensen A, Bang‐Andersen B, Vugts D, Beaino W. Visualization of brain targets with
89
Zr‐immuno‐PET using a novel bispecific amyloid ß monoclonal antibody. Alzheimers Dement 2021. [DOI: 10.1002/alz.053052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | | | - Iris Mes
- Amsterdam UMC, VU University Amsterdam Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Parker S, D'Angelo J, Buller RM, Smee DF, Lantto J, Nielsen H, Jensen A, Prichard M, George SL. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge. Antiviral Res 2021; 195:105179. [PMID: 34530009 PMCID: PMC9628779 DOI: 10.1016/j.antiviral.2021.105179] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Revised: 09/08/2021] [Accepted: 09/10/2021] [Indexed: 11/22/2022]
Abstract
Orthopoxviruses such as variola and monkeypox viruses continue to threaten the human population. Monkeypox virus is endemic in central and western Africa and outbreaks have reached as far as the U.S. Although variola virus, the etiologic agent of smallpox, has been eradicated by a successful vaccination program, official and likely clandestine stocks of the virus exist. Moreover, studies with ectromelia virus (the etiological agent of mousepox) have revealed that IL-4 recombinant viruses are significantly more virulent than wild-type viruses even in mice treated with vaccines and/or antivirals. For these reasons, it is critical that antiviral modalities are developed to treat these viruses should outbreaks, or deliberate dissemination, occur. Currently, 2 antivirals (brincidofovir and tecovirimat) are in the U.S. stockpile allowing for emergency use of the drugs to treat smallpox. Both antivirals have advantages and disadvantages in a clinical and emergency setting. Here we report on the efficacy of a recombinant immunoglobulin (rVIG) that demonstrated efficacy against several orthopoxviruses in vitro and in vivo in both a prophylactic and therapeutic fashion. A single intraperitoneal injection of rVIG significantly protected mice when given up to 14 days before or as late as 6 days post challenge. Moreover, rVIG reduced morbidity, as measured by weight-change, as well as several previously established biomarkers of disease. In rVIG treated mice, we found that vDNA levels in blood were significantly reduced, as was ALT (a marker of liver damage) and infectious virus levels in the liver. No apparent adverse events were observed in rVIG treated mice, suggesting the immunoglobulin is well tolerated. These findings suggest that recombinant immunoglobulins could be candidates for further evaluation and possible licensure under the FDA Animal Rule.
Collapse
Affiliation(s)
- Scott Parker
- Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University, and St. Louis VA Medical Center, St. Louis, MO, 63104, USA
| | - June D'Angelo
- Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University, and St. Louis VA Medical Center, St. Louis, MO, 63104, USA
| | - R Mark Buller
- Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO, 63104, USA
| | - Donald F Smee
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, 84322, USA
| | - Johan Lantto
- Symphogen, Pederstrupvej 93, DK-2750, Ballerup, Denmark
| | | | - Allan Jensen
- Symphogen, Pederstrupvej 93, DK-2750, Ballerup, Denmark
| | - Mark Prichard
- Department of Pediatrics, University of Alabama, Birmingham, AL, 35233, USA
| | - Sarah L George
- Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University, and St. Louis VA Medical Center, St. Louis, MO, 63104, USA.
| |
Collapse
|
30
|
Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O'Mara TA, Glubb DM, Tyrer JP, Armasu SM, Ong JS, Gharahkhani P, Lu Y, Gao B, Patch AM, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Velez Edwards DR, Beeghly-Fadiel A, Benitez J, Garcia MJ, Goodman MT, Dörk T, Dürst M, Modugno F, Moysich K, du Bois A, Pfisterer J, Bauman K, Karlan BY, Lester J, Cunningham JM, Larson MC, McCauley BM, Kjaer SK, Jensen A, Hogdall CK, Hogdall E, Schildkraut JM, Riggan MJ, Berchuck A, Cramer DW, Terry KL, Bjorge L, Webb PM, Friedlander M, Pejovic T, Moffitt M, Glasspool R, May T, Ene GEV, Huntsman DG, Woo M, Carney ME, Hinsley S, Heitz F, Fereday S, Kennedy CJ, Edwards SL, Winham SJ, deFazio A, Pharoah PDP, Goode EL, MacGregor S, Chenevix-Trench G. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2021; 30:1669-1680. [PMID: 34162658 PMCID: PMC8419101 DOI: 10.1158/1055-9965.epi-20-1817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 03/28/2021] [Accepted: 06/02/2021] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. METHODS We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. RESULTS We found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10-8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15-1.34; P = 1.47 × 10-8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. CONCLUSIONS The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. IMPACT This finding provides insight into genetic markers associated with EOC outcome and potential treatment options.See related commentary by Peres and Monteiro, p. 1604.
Collapse
Affiliation(s)
- Michael C J Quinn
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Karen McCue
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Wei Shi
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Sharon E Johnatty
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Jonathan Beesley
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Andrew Civitarese
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Tracy A O'Mara
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Dylan M Glubb
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Jonathan P Tyrer
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom
| | - Sebastian M Armasu
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | - Jue-Sheng Ong
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Puya Gharahkhani
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Yi Lu
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Bo Gao
- Crown Princess Mary Cancer Care Centre, Westmead Hospital, Sydney, New South Wales, Australia
- Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
| | - Ann-Marie Patch
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Peter A Fasching
- Division of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Matthias W Beckmann
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Diether Lambrechts
- VIB Center for Cancer Biology, VIB, Leuven, Belgium
- Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium
| | - Ignace Vergote
- Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - Digna R Velez Edwards
- Department of Obstetrics and Gynecology, Vanderbilt Epidemiology Center, Vanderbilt Genetics Institute, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Alicia Beeghly-Fadiel
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Javier Benitez
- Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - Maria J Garcia
- Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- Computational Oncology Group, Spanish National Cancer Centre (CNIO), Madrid, Spain
| | - Marc T Goodman
- Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
- Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Thilo Dörk
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Matthias Dürst
- Department of Gynecology, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany
| | - Francesmary Modugno
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
- Womens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania
| | - Kirsten Moysich
- Division of Cancer Prevention and Population Sciences, Cancer Pathology & Prevention, Roswell Park Cancer Institute, Buffalo, New York
| | - Andreas du Bois
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
- Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
| | | | | | - Beth Y Karlan
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
| | - Jenny Lester
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
| | - Julie M Cunningham
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Melissa C Larson
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | - Bryan M McCauley
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | - Susanne K Kjaer
- Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Allan Jensen
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Claus K Hogdall
- Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Estrid Hogdall
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Joellen M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
| | - Marjorie J Riggan
- Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
| | - Andrew Berchuck
- Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
| | - Daniel W Cramer
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Kathryn L Terry
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
- Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
| | - Line Bjorge
- Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | | | - Michael Friedlander
- Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
| | - Tanja Pejovic
- Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon
- Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
| | - Melissa Moffitt
- Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon
- Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
| | - Rosalind Glasspool
- Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom
| | - Taymaa May
- Division of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
| | - Gabrielle E V Ene
- Division of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
| | - David G Huntsman
- British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, BC Cancer Agency and University of British Columbia, British Columbia, Canada
- Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada
- Department of Obstetrics and Gynaecology, The University of British Columbia, Vancouver, British Columbia, Canada
- Department of Molecular Oncology, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Michelle Woo
- British Columbia's Ovarian Cancer Research (OVCARE) Program, Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Michael E Carney
- Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
| | - Samantha Hinsley
- Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom
| | - Florian Heitz
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
- Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
- Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - Sian Fereday
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Catherine J Kennedy
- Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia
| | - Stacey L Edwards
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Stacey J Winham
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | | | - Paul D P Pharoah
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom
- Strangeways Research Laboratory, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Worts Causeway, Cambridge, United Kingdom
| | - Ellen L Goode
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | - Stuart MacGregor
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
| |
Collapse
|
31
|
Händel MN, Jacobsen R, Thorsteinsdottir F, Keller AC, Stougaard M, Jensen CB, Moos C, Duus KS, Jensen A, Schiøler Kesmodel U, Abrahamsen B, Heitmann BL. Assessing Health Consequences of Vitamin D Fortification Utilizing a Societal Experiment Design: Methodological Lessons Learned from the D-Tect Project. Int J Environ Res Public Health 2021; 18:ijerph18158136. [PMID: 34360427 PMCID: PMC8345774 DOI: 10.3390/ijerph18158136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 07/16/2021] [Accepted: 07/23/2021] [Indexed: 11/16/2022]
Abstract
By utilizing historical changes in Danish legislation related to mandatory vitamin D fortification of margarine, which was implemented in the mid 1930s and abruptly abandoned in June 1985, the studies in the D-tect project investigated the effects of vitamin D on health outcomes in individuals, who during gestation were exposed or unexposed to extra vitamin D from fortified margarine. This paper reviews and narratively summarizes the analytic approaches alongside the results of the societal fortification experiment studies from the D-tect project and addresses the challenges in designing societal experiment studies and evaluating their results. The latter are discussed as lessons learned that may be useful for designers of similar studies, expected to be extensively utilized while researching the health consequences of the COVID-19 pandemic by comparing individuals born before and after the epidemic. In the D-tect project, 16 articles based on the societal fortification experiment were published analyzing 10 different outcomes and using different statistical approaches. Lessons learned included the detail of the analysis of the historical information on the exposure, availability and validity of the outcome data, variety of analytical approaches, and specifics concerning vitamin D effect evaluation, such as consideration of the influence of sunshine or season. In conclusion, the D-tect project clearly demonstrated the cost-effectiveness and research potential of natural- or societal-experiment-based studies.
Collapse
Affiliation(s)
- Mina Nicole Händel
- Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark; (F.T.); (C.M.); (K.S.D.); (B.L.H.)
- Correspondence:
| | - Ramune Jacobsen
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark;
| | - Fanney Thorsteinsdottir
- Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark; (F.T.); (C.M.); (K.S.D.); (B.L.H.)
| | - Amélie Cléo Keller
- Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark;
| | - Maria Stougaard
- Center for Early Intervention and Family Studies, Department of Psychology, University of Copenhagen, 1353 Copenhagen, Denmark;
| | - Camilla Bjørn Jensen
- Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark;
| | - Caroline Moos
- Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark; (F.T.); (C.M.); (K.S.D.); (B.L.H.)
| | - Katrine Sidenius Duus
- Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark; (F.T.); (C.M.); (K.S.D.); (B.L.H.)
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark;
| | - Ulrik Schiøler Kesmodel
- Department of Obstetrics and Gynaecology, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark;
| | - Bo Abrahamsen
- Open Patient Explorative Network, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark;
- Department of Medicine, Holbæk Hospital, 4300 Holbæk, Denmark
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7FY, UK
| | - Berit Lilienthal Heitmann
- Research Unit for Dietary Studies, The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark; (F.T.); (C.M.); (K.S.D.); (B.L.H.)
- Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark;
- The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, Sydney, NSW 2006, Australia
| |
Collapse
|
32
|
Kar SP, Considine DP, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN, Rajagopal PS, Rosenow WT, Moreno F, Bodelon C, Chang-Claude J, Chenevix-Trench G, deFazio A, Dörk T, Ekici AB, Ewing A, Fountzilas G, Goode EL, Hartman M, Heitz F, Hillemanns P, Høgdall E, Høgdall CK, Huzarski T, Jensen A, Karlan BY, Khusnutdinova E, Kiemeney LA, Kjaer SK, Klapdor R, Köbel M, Li J, Liebrich C, May T, Olsson H, Permuth JB, Peterlongo P, Radice P, Ramus SJ, Riggan MJ, Risch HA, Saloustros E, Simard J, Szafron LM, Titus L, Thompson CL, Vierkant RA, Winham SJ, Zheng W, Doherty JA, Berchuck A, Lawrenson K, Im HK, Manichaikul AW, Pharoah PD, Gayther SA, Schildkraut JM. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv 2021; 2:100042. [PMID: 34317694 PMCID: PMC8312632 DOI: 10.1016/j.xhgg.2021.100042] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Accepted: 06/04/2021] [Indexed: 12/12/2022] Open
Abstract
Familial, sequencing, and genome-wide association studies (GWASs) and genetic correlation analyses have progressively unraveled the shared or pleiotropic germline genetics of breast and ovarian cancer. In this study, we aimed to leverage this shared germline genetics to improve the power of transcriptome-wide association studies (TWASs) to identify candidate breast cancer and ovarian cancer susceptibility genes. We built gene expression prediction models using the PrediXcan method in 681 breast and 295 ovarian tumors from The Cancer Genome Atlas and 211 breast and 99 ovarian normal tissue samples from the Genotype-Tissue Expression project and integrated these with GWAS meta-analysis data from the Breast Cancer Association Consortium (122,977 cases/105,974 controls) and the Ovarian Cancer Association Consortium (22,406 cases/40,941 controls). The integration was achieved through application of a pleiotropy-guided conditional/conjunction false discovery rate (FDR) approach in the setting of a TWASs. This identified 14 candidate breast cancer susceptibility genes spanning 11 genomic regions and 8 candidate ovarian cancer susceptibility genes spanning 5 genomic regions at conjunction FDR < 0.05 that were >1 Mb away from known breast and/or ovarian cancer susceptibility loci. We also identified 38 candidate breast cancer susceptibility genes and 17 candidate ovarian cancer susceptibility genes at conjunction FDR < 0.05 at known breast and/or ovarian susceptibility loci. The 22 genes identified by our cross-cancer analysis represent promising candidates that further elucidate the role of the transcriptome in mediating germline breast and ovarian cancer risk.
Collapse
Affiliation(s)
- Siddhartha P. Kar
- Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Daniel P.C. Considine
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Jonathan P. Tyrer
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Jasmine T. Plummer
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - Stephanie Chen
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - Felipe S. Dezem
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - Alvaro N. Barbeira
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Padma S. Rajagopal
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Will T. Rosenow
- Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
| | - Fernando Moreno
- Department of Oncology, Hospital Clínico San Carlos, Madrid, Spain
| | - Clara Bodelon
- Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Anna deFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia
| | - Thilo Dörk
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Arif B. Ekici
- Institute of Human Genetics, University Hospital Erlangen, Erlangen, Germany
- Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen, Erlangen, Germany
| | - Ailith Ewing
- MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
| | - George Fountzilas
- Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
| | - Ellen L. Goode
- Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - Mikael Hartman
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore
| | - Florian Heitz
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang., Essen, Germany
- Department of Gynecology, Center for Oncologic Surgery, Charité Campus Virchow-Klinikum, Berlin, Germany
| | - Peter Hillemanns
- Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany
| | - Estrid Høgdall
- Department of Virus, Lifestyle, and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Claus K. Høgdall
- The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Tomasz Huzarski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
- Department of Genetics and Pathology, University of Zielona Góra, Zielona Góra, Poland
| | - Allan Jensen
- Department of Lifestyle, Reproduction, and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Beth Y. Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA
| | - Elza Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia
- Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russia
| | - Lambertus A. Kiemeney
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Susanne K. Kjaer
- Department of Virus, Lifestyle, and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Rüdiger Klapdor
- Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany
| | - Martin Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada
| | - Jingmei Li
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore
- Genome Institute of Singapore, Human Genetics, Singapore, Singapore
| | - Clemens Liebrich
- Department of Obstetrics and Gynecology, Klinikum Wolfsburg, Wolfsburg, Germany
| | - Taymaa May
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
| | - Håkan Olsson
- Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Jennifer B. Permuth
- Departments of Cancer Epidemiology and Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Paolo Peterlongo
- Genome Diagnostics Program, IFOM-The FIRC Institute of Molecular Oncology, Milan, Italy
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy
| | - Susan J. Ramus
- School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - Marjorie J. Riggan
- Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
| | - Harvey A. Risch
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
| | | | - Jacques Simard
- Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec City, QC, Canada
| | - Lukasz M. Szafron
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Linda Titus
- Muskie School of Public Service, University of Southern Maine, Portland, ME, USA
| | - Cheryl L. Thompson
- Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA
| | - Robert A. Vierkant
- Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA
| | - Stacey J. Winham
- Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Jennifer A. Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Andrew Berchuck
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
| | - Kate Lawrenson
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Hae Kyung Im
- Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
| | - Ani W. Manichaikul
- Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
- Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA
| | - Paul D.P. Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Simon A. Gayther
- Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Joellen M. Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| |
Collapse
|
33
|
Bandak M, Jensen A, Dehlendorff C, Lauritsen J, Kreiberg M, Wagner T, Rosenvilde J, Daugaard G. Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort Study. J Natl Cancer Inst 2021; 114:149-155. [PMID: 34180995 DOI: 10.1093/jnci/djab130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/26/2021] [Accepted: 06/25/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Testicular germ cell cancer (TC) incidence peaks in the reproductive age but knowledge on fertility after treatment is insufficient. The aim was to evaluate paternity after today's testicular cancer (TC) treatment. METHODS Clinical data were extracted from the Danish Testicular Cancer database and patients were divided into four groups: 1) Surveillance; 2) Bleomycin, etoposide, and cisplatin (BEP); 3) BEP + post-chemotherapy retroperitoneal surgery (BEP + surgery); and 4) Abdominal radiotherapy. For each patient, 10 men matched on date of birth were randomly sampled from the normal population. Paternity was defined as date of birth of first child after TC treatment with or without the use of assisted reproductive technology (ART) and was assessed by linkage to the Danish Medical Birth Register and the Danish in vitro fertilization (IVF)-register. RESULTS We included 4,846 unilateral TC patients and 48,456 men from the normal population. The 20 years predicted chance of obtaining fatherhood for a 30-year-old man was 39.7% in TC patients compared to 42.5 % in the normal population. The chance of obtaining fatherhood was statistically significantly decreased after BEP (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.78-0.97) and BEP + surgery (HR = 0.74 95% CI = 0.63-0.87), but not after radiotherapy (HR = 0.89, 95% CI = 0.75-1.06) or surveillance (HR = 0.95, 95% CI = 0.89-1.02). The risk of needing ART to obtain fatherhood was increased after all treatment modalities. CONCLUSION The chance of obtaining fatherhood after TC treatment was substantially higher than previously reported. Patients followed on a surveillance program had a similar chance of obtaining fatherhood as non-cancerous men.
Collapse
Affiliation(s)
- Mikkel Bandak
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Allan Jensen
- Virus, Lifestyle and Genes. Danish Cancer Society Research Center. Danish Cancer Society, Copenhagen, Denmark
| | - Christian Dehlendorff
- Statistics and Dataanalysis, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| | - Jakob Lauritsen
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Michael Kreiberg
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Thomas Wagner
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Josephine Rosenvilde
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Gedske Daugaard
- Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
34
|
Stergiou N, Wünsche E, Mes I, Schreurs M, Verlaan M, Kooijman E, Windhorst A, Dongen G, Helboe L, Vergo S, Christensen S, Asuni A, Jensen A, Bang-Andersen B, Vugts D, Beaino W. Corrigendum to “SSP-27: 89Zr-immuno-PET of a novel bispecific amyloid β monoclonal antibody reveals improved and high specific brain uptake” [Nucl Med Biol (2020) Volumes 96–97, Supplement. S30-S31]. Nucl Med Biol 2021. [DOI: 10.1016/j.nucmedbio.2021.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Christensen SC, Hudecz D, Jensen A, Christensen S, Nielsen MS. Basigin Antibodies with Capacity for Drug Delivery Across Brain Endothelial Cells. Mol Neurobiol 2021; 58:4392-4403. [PMID: 34014436 DOI: 10.1007/s12035-021-02421-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 05/04/2021] [Indexed: 01/06/2023]
Abstract
The blood-brain barrier (BBB) poses challenges for delivering antibody-based therapeutics to the brain and is a main obstacle for the successful application of biotherapeutics for the treatment of brain disorders. As only a small fraction of monoclonal antibodies (mAbs) is penetrating the BBB, high doses of therapeutics are required to elicit a pharmacological effect. This limitation has evoked research to improve transport across the BBB through receptor-mediated transcytosis, and several receptors have been explored for mediating this process. A recently suggested candidate is the brain endothelial cells (BECs) expressed basigin. Here, we explore the transcytosis capacity of different basigin mAbs targeting distinct epitopes using the porcine in vitro BBB models and provide data showing the intracellular vesicle sorting of these basigin mAbs in porcine BECs. Our data suggest that basigin mAbs avoid the lysosomal degradation pathway and are internalized to vesicles used by recycling receptors. Engagement of basigin mAbs with basigin led to the translocation of the mAbs across the tight BECs into the astrocytes in our in vitro BBB co-culture model. Although mAbs with higher binding affinity to basigin showed a greater astrocyte internalization, based on our experiments, it is not clear whether the transcytosis is affinity- or epitope-dependent or a combination of both. Overall, this study provides information about the intra- and intercellular fate of basigin mAbs in BECs, which are valuable for the future design of basigin-mediated drug delivery platforms.
Collapse
Affiliation(s)
- Sarah Christine Christensen
- Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, Building 1116, 8000, Aarhus C, Denmark.,Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Diána Hudecz
- Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, Building 1116, 8000, Aarhus C, Denmark
| | - Allan Jensen
- Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Søren Christensen
- Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Morten Schallburg Nielsen
- Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, Building 1116, 8000, Aarhus C, Denmark.
| |
Collapse
|
36
|
Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, Rossing MA, Duerst M, Dork T, Bogdanova NV, Modugno F, Moysich K, Odunsi K, Ness R, Karlan BY, Lester J, Jensen A, Krüger Kjaer S, Høgdall E, Campbell IG, Lázaro C, Pujara MA, Cunningham J, Vierkant R, Winham SJ, Hildebrandt M, Huff C, Li D, Wu X, Yu Y, Permuth JB, Levine DA, Schildkraut JM, Riggan MJ, Berchuck A, Webb PM, Group OS, Cybulski C, Gronwald J, Jakubowska A, Lubinski J, Alsop J, Harrington P, Chan I, Menon U, Pearce CL, Wu AH, de Fazio A, Kennedy CJ, Goode E, Ramus S, Gayther S, Pharoah P. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet 2021; 58:305-313. [PMID: 32546565 PMCID: PMC8086250 DOI: 10.1136/jmedgenet-2019-106739] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 03/13/2020] [Accepted: 05/12/2020] [Indexed: 11/19/2022]
Abstract
PURPOSE The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes. METHODS We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases versus controls were further examined in an independent set of 14 135 EOC cases and 28 655 controls from the Ovarian Cancer Association Consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics. RESULTS The ORs associated for high-grade serous ovarian cancer were 3.01 for PALB2 (95% CI 1.59 to 5.68; p=0.00068), 1.99 for POLK (95% CI 1.15 to 3.43; p=0.014) and 4.07 for SLX4 (95% CI 1.34 to 12.4; p=0.013). Deleterious mutations in FBXO10 were associated with a reduced risk of disease (OR 0.27, 95% CI 0.07 to 1.00, p=0.049). However, based on the Bayes false discovery probability, only the association for PALB2 in high-grade serous ovarian cancer is likely to represent a true positive. CONCLUSIONS We have found strong evidence that carriers of PALB2 deleterious mutations are at increased risk of high-grade serous ovarian cancer. Whether the magnitude of risk is sufficiently high to warrant the inclusion of PALB2 in cancer gene panels for ovarian cancer risk testing is unclear; much larger sample sizes will be needed to provide sufficiently precise estimates for clinical counselling.
Collapse
Affiliation(s)
- Honglin Song
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Ed M Dicks
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Jonathan Tyrer
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Maria Intermaggio
- School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Georgia Chenevix-Trench
- Cancer Genetics, Queensland Institute of Medical Research-QIMR, Herston, Queensland, Australia
| | - David D Bowtell
- Cancer Genomics and Genetics and Women's Cancer Programs, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Nadia Traficante
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
| | - Aocs Group
- QIMR Berghofer Department of Genetics and Computational Biology, Herston, Queensland, Australia
- Department of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - James Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Teodora Goranova
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Karen Hosking
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Anna Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Elke van Oudenhove
- Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York, USA
| | - Jen Doherty
- Huntsman Institute, University of Utah, Salt Lake City, Utah, USA
| | - Holly R Harris
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- Department of Epidemiology, University of Washington, Seattle, Washington, USA
| | - Mary Anne Rossing
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- Department of Epidemiology, University of Washington, Seattle, Washington, USA
| | - Matthias Duerst
- Department of Gynaecology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Thüringen, Germany
| | - Thilo Dork
- Gynaecology Research Unit, Hannover Medical School, Hannover, Niedersachsen, Germany
| | - Natalia V Bogdanova
- Department of Radiation Oncology, Hannover Medical School, Hannover, Niedersachsen, Germany
- Department of Gynaecology, NN Alexandrov National Cancer Centre, Minsk, Minsk, Belarus
| | - Francesmary Modugno
- Womens Cancer Research Center, Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Kirsten Moysich
- Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - Kunle Odunsi
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - Roberta Ness
- School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Beth Y Karlan
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Jenny Lester
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Kobenhavn, Denmark
| | - Susanne Krüger Kjaer
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark
| | - Estrid Høgdall
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Kobenhavn, Denmark
- Department of Pathology, Herlev Hospital, University of Copenhagen, Kobenhavn, Denmark
| | - Ian G Campbell
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
- Department of Research, Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Conxi Lázaro
- Hereditary Cancer Program, Catalan Institute of Oncology, Barcelona, Catalunya, Spain
| | - Miguel Angel Pujara
- Translational Research Laboratory, Catalan Institute of Oncology, Barcelona, Catalunya, Spain
| | - Julie Cunningham
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | - Robert Vierkant
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
| | - Stacey J Winham
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
| | - Michelle Hildebrandt
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Chad Huff
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Donghui Li
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Xifeng Wu
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Yao Yu
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jennifer B Permuth
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Douglas A Levine
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York University, New York, New York, USA
| | - Joellen M Schildkraut
- Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA
| | - Marjorie J Riggan
- Department of Gynecologic Oncology, Duke University Hospital, Durham, North Carolina, USA
| | - Andrew Berchuck
- Department of Gynecologic Oncology, Duke University Hospital, Durham, North Carolina, USA
| | - Penelope M Webb
- Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Opal Study Group
- Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Cezary Cybulski
- Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Zachodniopomorskie, Poland
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Zachodniopomorskie, Poland
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Zachodniopomorskie, Poland
- Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Zachodniopomorskie, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Zachodniopomorskie, Poland
| | - Jennifer Alsop
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Patricia Harrington
- Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire, UK
| | - Isaac Chan
- School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Usha Menon
- MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, London, UK
| | - Celeste L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Anna de Fazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia
| | - Catherine J Kennedy
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia
| | - Ellen Goode
- Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Susan Ramus
- School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
- Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Simon Gayther
- Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Paul Pharoah
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| |
Collapse
|
37
|
Stergiou N, Wünsche T, Mes I, Schreurs M, Verlaan M, Kooijman E, Windhorst A, van Dongen G, Helboe L, Vergo S, Christensen S, Asuni A, Jensen A, Bang-Andersen B, Vugts D, Beaino W. 89Zr-immuno-PET of a novel bispecific amyloid-β monoclonal antibody reveals improved and high specific brain uptake. Nucl Med Biol 2021. [DOI: 10.1016/s0969-8051(21)00314-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Freund L, Kjær SK, Guleria S, Albieri V, Nybo Andersen AM, Frederiksen K, Jensen A. Use of Fertility Drugs and Risk of Malignant Melanoma: Results from a Large Danish Population-Based Cohort Study. J Invest Dermatol 2021; 141:2189-2196.e1. [PMID: 33741390 DOI: 10.1016/j.jid.2021.02.752] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 02/04/2021] [Accepted: 02/11/2021] [Indexed: 10/21/2022]
Abstract
Fertility drugs have not definitively been linked to malignant melanoma. By the use of data from a large nationwide cohort of women aged 20.0-45.0 years and living in Denmark between January 1, 1995 and December 31, 2011, we assessed the association between the use of fertility drugs and the risk of malignant melanoma. Information on fertility status and the use of fertility drugs was obtained from the population-based Danish Infertility Cohort. Cox proportional hazard regression models were applied to estimate hazard ratios and 95% confidence intervals with adjustment for potential confounders. The study population comprised 1,330,954 women, of whom 86,231 (6.5%) were treated with fertility drugs. During a median follow-up of 21.0 years, 6,139 women were diagnosed with malignant melanoma. Compared with fertile women, women with fertility challenges who had used any fertility drugs had an increased risk of malignant melanoma (hazard ratio = 1.14; 95% confidence interval = 1.02-1.27). Furthermore, the use of specific types of fertility drugs (clomiphene, gonadotropins, human chorionic gonadotropin, gonadotropin-releasing hormone preparations, and progesterone) was also associated with an increased risk of malignant melanoma, with hazard ratios ranging between 1.09 and 1.13; however, the association did not reach statistical significance. Our findings indicate that the use of fertility drugs was associated with a modestly increased risk of malignant melanoma.
Collapse
Affiliation(s)
- Linn Freund
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Sonia Guleria
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Vanna Albieri
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Anne-Marie Nybo Andersen
- Section for Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Kirsten Frederiksen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Allan Jensen
- Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark.
| |
Collapse
|
39
|
Lee AW, Rosenzweig S, Wiensch A, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. J Natl Cancer Inst 2021; 113:301-308. [PMID: 32766851 PMCID: PMC7936053 DOI: 10.1093/jnci/djaa099] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Revised: 06/08/2020] [Accepted: 06/29/2020] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Parity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated. METHODS A pooled analysis of 10 470 invasive epithelial ovarian cancer cases and 16 942 controls was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race and ethnicity, age, and education level and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses. RESULTS Ever having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (2-sided Ptrend < .001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer. CONCLUSIONS Incomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk.
Collapse
Affiliation(s)
- Alice W Lee
- Department of Public Health, California State University, Fullerton, Fullerton, CA, USA
| | - Stacey Rosenzweig
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Ashley Wiensch
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | | | - Susan J Ramus
- School of Women’s and Children’s Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia
| | - Usha Menon
- MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - Aleksandra Gentry-Maharaj
- MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - Argyrios Ziogas
- Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA
| | - Hoda Anton-Culver
- Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA
| | - Alice S Whittemore
- Department of Epidemiology and Public Health, Stanford University School of Medicine, Stanford, CA, USA
- Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA
| | - Weiva Sieh
- Departments of Genetics and Genomic Sciences and of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Joseph H Rothstein
- Departments of Genetics and Genomic Sciences and of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Valerie McGuire
- Department of Epidemiology and Public Health, Stanford University School of Medicine, Stanford, CA, USA
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Elisa V Bandera
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Bo Qin
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Kathryn L Terry
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Daniel W Cramer
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Linda Titus
- Public Health, Muskie School of Public Service, University of Southern Maine, Portland, ME, USA
| | - Joellen M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Andrew Berchuck
- Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
| | - Ellen L Goode
- Division of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susan J Jordan
- School of Public Health, The University of Queensland, Brisbane, Australia
| | - Roberta B Ness
- School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Francesmary Modugno
- Womens Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Kirsten Moysich
- Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Pamela J Thompson
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Michael E Carney
- Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Mary Anne Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Jennifer Anne Doherty
- Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | - Harvey A Risch
- Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
| | - Lilah Khoja
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Aliya Alimujiang
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Minh Tung Phung
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Katharine Brieger
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Bhramar Mukherjee
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Paul D P Pharoah
- Department of Oncology, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Malcolm C Pike
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Penelope M Webb
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Celeste Leigh Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| |
Collapse
|
40
|
Wienecke LS, Kjær SK, Frederiksen K, Hargreave M, Dalton SO, Jensen A. Ninth-grade school achievement in Danish children conceived following fertility treatment: a population-based cohort study. Fertil Steril 2021; 113:1014-1023. [PMID: 32386613 DOI: 10.1016/j.fertnstert.2020.01.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 01/03/2020] [Accepted: 01/06/2020] [Indexed: 01/12/2023]
Abstract
OBJECTIVE To assess whether academic achievement among children conceived following fertility treatment is different from that of children born to fertile women while also considering the underlying infertility. DESIGN Population-based cohort study. SETTING Denmark. PATIENT(S) The study population consisted of all 154,536 firstborn, live-born, singleton children in Denmark between 1995 and 2000 who completed their ninth grade with an examination. INTERVENTION(S) The Danish Infertility Cohort was used to identify children conceived after fertility treatment (n = 10,099), and information on mean school marks was obtained from Statistics Denmark. MAIN OUTCOME MEASURE(S) Linear regression models were used to estimate mean differences (MDs) and 95% confidence intervals (CIs). Multiple logistic regression models were used to estimate odds ratios (OR) and 95% CI of not passing the ninth-grade examination. RESULTS The crude overall mean marks for children conceived after the various fertility treatment procedures were in general higher than in children born to fertile women. However, after adjustment for potential confounders, the overall mean marks were statistically significantly lower for children conceived after the various fertility treatment procedures (e.g., any fertility treatment: MD -0.13; 95% CI -0.18, -0.08) compared with children born to fertile women. Further, children conceived after any fertility treatment had a statistically significant lower crude likelihood of not passing the ninth-grade examination (OR 0.66; 95% CI 0.53, 0.81) compared with children born to fertile women, whereas no difference was observed in the confounder adjusted analyses (OR 1.15; 95% CI 0.89, 1.49). When children born to women requiring fertility assistance but without fertility treatment in the index pregnancy were used as a reference group, no differences in the adjusted overall mean marks and the likelihood of not passing the ninth grade with an examination were observed. CONCLUSION Our findings indicate that fertility treatment per se is not associated with lower school marks and the likelihood of not passing the ninth grade with an examination. Hence, we suggest that factors related to both fertility problems and cognitive development may more likely explain the slightly lower academic performance (i.e., modest lower mean marks) among children conceived after fertility treatment.
Collapse
Affiliation(s)
- Lisa S Wienecke
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Kirsten Frederiksen
- Statistics and Epidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Marie Hargreave
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne O Dalton
- Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Næstved, Denmark
| | - Allan Jensen
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
| |
Collapse
|
41
|
Guleria S, Jensen A, Albieri V, Nøhr B, Frederiksen K, Kjær SK. Endometrial cancer risk after fertility treatment: a population-based cohort study. Cancer Causes Control 2021; 32:181-188. [PMID: 33392904 DOI: 10.1007/s10552-020-01372-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 11/18/2020] [Indexed: 01/23/2023]
Abstract
PURPOSE Using data from a large population-based cohort of women with fertility problems in Denmark, we examined the association between use of fertility drugs and endometrial cancer incidence. METHODS Women aged 20-45 years living in Denmark during 1 January 1995-31 December 2017 and diagnosed with fertility problems (i.e., subfertile women) were identified from the Danish Infertility Cohort. Information on use of fertility drugs, endometrial cancer, covariates and vital status was obtained from various Danish national registers. Cox proportional hazard models were used adjusted for calendar year of study entry, highest level of education, parity status, hormonal contraceptive use, obesity and diabetes mellitus. RESULTS Of the 146,104 subfertile women, 129,478 (88.6%) were treated with fertility drugs. During a median follow-up of 10.1 years, 119 women were diagnosed with endometrial cancer. Use of any fertility drugs was not associated with an increased rate of overall (HR 0.82; 95% CI 0.50-1.34) or type I endometrial cancer (HR 1.08; 95% CI 0.60-1.95). No associations between use of specific types of fertility drugs and endometrial cancer were observed. No marked associations were observed according to cumulative dose of specific fertility drugs, parity status, or with increasing follow-up time. CONCLUSIONS No marked associations between use of fertility drugs and risk of endometrial cancer were observed. The relatively young age of the cohort at end of follow-up, however, highlights the need for longer follow-up of women after fertility drug use.
Collapse
Affiliation(s)
- Sonia Guleria
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Allan Jensen
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Vanna Albieri
- Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark
| | - Bugge Nøhr
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.,Department of Obstetrics and Gynecology, University Hospital of Herlev and Gentofte, Copenhagen, Denmark
| | - Kirsten Frederiksen
- Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark
| | - Susanne K Kjær
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. .,Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
42
|
Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards DV, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiol Biomarkers Prev 2021; 30:217-228. [PMID: 33144283 DOI: 10.1158/1055-9965.epi-20-0739] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 07/31/2020] [Accepted: 10/22/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. METHODS Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. RESULTS Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (P Bonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. CONCLUSIONS Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. IMPACT Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.
Collapse
Affiliation(s)
- Dylan M Glubb
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Deborah J Thompson
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Katja K H Aben
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands
| | - Ahmad Alsulimani
- Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Frederic Amant
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals KU Leuven, University of Leuven, Leuven, Belgium
| | - Daniela Annibali
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals KU Leuven, University of Leuven, Leuven, Belgium
| | - John Attia
- Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales, Australia
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
| | - Aurelio Barricarte
- CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Matthias W Beckmann
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Andrew Berchuck
- Department of Gynecologic Oncology, Duke University Hospital, Durham, North Carolina
| | - Marina Bermisheva
- Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia
| | - Marcus Q Bernardini
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Katharina Bischof
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Line Bjorge
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Clara Bodelon
- Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland
| | - Alison H Brand
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia
- University of Sydney, Sydney, New South Wales, Australia
| | - James D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Louise A Brinton
- Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland
| | - Fiona Bruinsma
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
| | - Daniel D Buchanan
- Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia
- University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia
| | - Stefanie Burghaus
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Ralf Butzow
- Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Hui Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Michael E Carney
- John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, Hawaii
| | - Stephen J Chanock
- Division of Cancer Epidemiology and Genetics, NCI, NIH, Department of Health and Human Services, Bethesda, Maryland
| | - Chu Chen
- Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Xiao Qing Chen
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Zhihua Chen
- Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida
| | - Linda S Cook
- University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, New Mexico
- Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada
| | - Julie M Cunningham
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Immaculata De Vivo
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Anna deFazio
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia
| | - Jennifer A Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah
| | - Thilo Dörk
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Andreas du Bois
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
- Praxis für Humangenetik, Wiesbaden, Germany
| | - Alison M Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Matthias Dürst
- Department of Gynaecology, Jena University Hospital- Friedrich Schiller University, Jena, Germany
| | - Todd Edwards
- Division of Epidemiology, Center for Human Genetics Research, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Robert P Edwards
- Ovarian Cancer Center of Excellence, Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Arif B Ekici
- Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Ailith Ewing
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Peter A Fasching
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California
| | - Sarah Ferguson
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - James M Flanagan
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
| | - Florentia Fostira
- Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos," Athens, Greece
| | - George Fountzilas
- Second Department of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
| | - Christine M Friedenreich
- Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada
| | - Bo Gao
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia
- The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, New South Wales, Australia
| | - Mia M Gaudet
- Department of Population Science, American Cancer Society, Atlanta, Georgia
| | - Jan Gawełko
- Institute of Nursing and Health Sciences, Medical Faculty, University of Rzeszów, Rzeszów, Poland
| | - Aleksandra Gentry-Maharaj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
| | - Graham G Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Rosalind Glasspool
- Department of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
- Department of Epidemiology, University of Washington, Seattle, Washington
| | - Philipp Harter
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | - Alexander Hein
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Florian Heitz
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | | | - Peter Hillemanns
- Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Estrid Høgdall
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Claus K Høgdall
- The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Elizabeth G Holliday
- Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales, Australia
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
| | - David G Huntsman
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
| | - Tomasz Huzarski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
- Department of Genetics and Pathology, University of Zielona Góra, Zielona Góra, Poland
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Michael E Jones
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - Beth Y Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California
| | - Anthony Karnezis
- Department of Pathology and Laboratory Medicine, UC Davis Medical Center, Sacramento, California
| | - Joseph L Kelley
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Elza Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia
- Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russia
| | - Jeffrey L Killeen
- Department of Pathology, Kapiolani Medical Center for Women and Children, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Rüdiger Klapdor
- Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany
| | - Martin Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada
| | - Bozena Konopka
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Irene Konstantopoulou
- Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos," Athens, Greece
| | - Reidun K Kopperud
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Madhuri Koti
- Departments of Biomedical and Molecular Sciences and Obstetrics and Gynaecology, Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada
| | - Peter Kraft
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
- Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Jolanta Kupryjanczyk
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Diether Lambrechts
- VIB Center for Cancer Biology, Leuven, Belgium
- Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium
| | - Melissa C Larson
- Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
| | - Loic Le Marchand
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
| | - Shashikant Lele
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
| | - Jenny Lester
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California
| | - Andrew J Li
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Dong Liang
- College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas
| | - Clemens Liebrich
- Clinics of Gynaecology, Cancer Center Wolfsburg, Wolfsburg, Germany
| | - Loren Lipworth
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center, Oncology Institute, Warsaw, Poland
| | - Lingeng Lu
- Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
| | - Karen H Lu
- Department of Gynecologic Oncology and Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Alessandra Macciotta
- Evangelische Kliniken Essen-Mitte Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Germany
| | - Amalia Mattiello
- Dipertimento Di Medicina Clinca e Chirurgia, Federico II University, Naples, Italy
| | - Taymaa May
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Jessica N McAlpine
- British Columbia's Ovarian Cancer Research (OVCARE) Program-Gynecologic Tissue Bank, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver General Hospital and BC Cancer, Vancouver, BC, Canada
| | - Valerie McGuire
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California
| | - Iain A McNeish
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery and Cancer, Imperial College London, London, UK
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Usha Menon
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
| | - Francesmary Modugno
- Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
- Womens Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania
| | - Kirsten B Moysich
- Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Kunle Odunsi
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
| | - Håkan Olsson
- Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden
| | - Sandra Orsulic
- Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Ana Osorio
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
- Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
| | | | - Celeste L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | - Tanja Pejovic
- Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon
- Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon
| | - Jennifer B Permuth
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - Agnieszka Podgorska
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Susan J Ramus
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia
| | - Timothy R Rebbeck
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Marjorie J Riggan
- Department of Gynecologic Oncology, Duke University Hospital, Durham, North Carolina
| | - Harvey A Risch
- Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
| | - Joseph H Rothstein
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Ingo B Runnebaum
- Department of Gynaecology, Jena University Hospital- Friedrich Schiller University, Jena, Germany
| | - Rodney J Scott
- Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales, Australia
- Division of Molecular Medicine, Pathology North, John Hunter Hospital, Newcastle, New South Wales, Australia
- Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia
| | - Thomas A Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - Janine Senz
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Veronica Wendy Setiawan
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Nadeem Siddiqui
- Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, UK
| | - Weiva Sieh
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
| | | | - Rebecca Sutphen
- Epidemiology Center, College of Medicine, University of South Florida, Tampa, Florida
| | - Anthony J Swerdlow
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
- Division of Breast Cancer Research, The Institute of Cancer Research, London, UK
| | - Lukasz Michael Szafron
- Department of Immunology, the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland
| | - Soo Hwang Teo
- Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
- Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Pamela J Thompson
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California
| | - Liv Cecilie Vestrheim Thomsen
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Linda Titus
- Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire
| | - Alicia Tone
- Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Rosario Tumino
- Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Berlin, Germany
| | - Constance Turman
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Adriaan Vanderstichele
- Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - Digna Velez Edwards
- Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Ignace Vergote
- Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - Robert A Vierkant
- Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
| | - Zhaoming Wang
- Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland
| | - Shan Wang-Gohrke
- Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - Penelope M Webb
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Emily White
- Department of Epidemiology, University of Washington, Seattle, Washington
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Alice S Whittemore
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California
- Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California
| | - Stacey J Winham
- Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
| | - Xifeng Wu
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Drakoulis Yannoukakos
- Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos," Athens, Greece
| | - Amanda B Spurdle
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Tracy A O'Mara
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
| |
Collapse
|
43
|
Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomäki K, Pelttari LM, Ehrencrona H, Borg Å, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, Dennis J, Bowtell DD, Traficante N, Diez O, Balmaña J, Gruber SB, Chenevix-Trench G, Investigators KC, Jensen A, Kjær SK, Høgdall E, Castéra L, Garber J, Janavicius R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler RK, Pharoah PDP, Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst 2020; 112:1242-1250. [PMID: 32107557 PMCID: PMC7735771 DOI: 10.1093/jnci/djaa030] [Citation(s) in RCA: 85] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 02/07/2020] [Accepted: 02/25/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C and RAD51D. METHODS We analyzed data from 6178 families, 125 with pathogenic variants in RAD51C, and 6690 families, 60 with pathogenic variants in RAD51D. TOC and BC relative and cumulative risks were estimated using complex segregation analysis to model the cancer inheritance patterns in families while adjusting for the mode of ascertainment of each family. All statistical tests were two-sided. RESULTS Pathogenic variants in both RAD51C and RAD51D were associated with TOC (RAD51C: relative risk [RR] = 7.55, 95% confidence interval [CI] = 5.60 to 10.19; P = 5 × 10-40; RAD51D: RR = 7.60, 95% CI = 5.61 to 10.30; P = 5 × 10-39) and BC (RAD51C: RR = 1.99, 95% CI = 1.39 to 2.85; P = 1.55 × 10-4; RAD51D: RR = 1.83, 95% CI = 1.24 to 2.72; P = .002). For both RAD51C and RAD51D, there was a suggestion that the TOC relative risks increased with age until around age 60 years and decreased thereafter. The estimated cumulative risks of developing TOC to age 80 years were 11% (95% CI = 6% to 21%) for RAD51C and 13% (95% CI = 7% to 23%) for RAD51D pathogenic variant carriers. The estimated cumulative risks of developing BC to 80 years were 21% (95% CI = 15% to 29%) for RAD51C and 20% (95% CI = 14% to 28%) for RAD51D pathogenic variant carriers. Both TOC and BC risks for RAD51C and RAD51D pathogenic variant carriers varied by cancer family history and could be as high as 32-36% for TOC, for carriers with two first-degree relatives diagnosed with TOC, or 44-46% for BC, for carriers with two first-degree relatives diagnosed with BC. CONCLUSIONS These estimates will facilitate the genetic counseling of RAD51C and RAD51D pathogenic variant carriers and justify the incorporation of RAD51C and RAD51D into cancer risk prediction models.
Collapse
Affiliation(s)
- Xin Yang
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Honglin Song
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Goska Leslie
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Christoph Engel
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - Eric Hahnen
- Faculty of Medicine and University Hospital Cologne, Center for Familial Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, University of Cologne, Cologne, Germany
| | - Bernd Auber
- Institute of Human Genetics, Hannover Medical School, Hannover, Germany
| | - Judit Horváth
- Institute of Human Genetics, University of Münster, Münster, Germany
| | - Karin Kast
- Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
- German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dieter Niederacher
- Department of Gynecology and Obstetrics, Heinrich-Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Clare Turnbull
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - Richard Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - Helen Hanson
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - Chey Loveday
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | | | | | - Susan J Ramus
- School of Women’s and Children’s Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia
- Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, New South Wales, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia
| | - Usha Menon
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
| | - Adam N Rosenthal
- Women’s Cancer, Institute for Women’s Health, University College London, London, UK
| | - Ian Jacobs
- Women’s Cancer, Institute for Women’s Health, University College London, London, UK
- University of New South Wales, Sydney, New South Wales, Australia
- University of Manchester, Manchester, UK
| | - Simon A Gayther
- Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Ed Dicks
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Kristiina Aittomäki
- Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Liisa M Pelttari
- Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Hans Ehrencrona
- Department of Clinical Genetics and Pathology, Laboratory Medicine, Office for Medical Services, Region Skåne, Lund, Sweden
- Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Åke Borg
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - Anders Kvist
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - Barbara Rivera
- Gerald Bronfman Dept Oncology, Jewish General Hospital, McGill University and Lady Davis Institute, Montréal, QC, Canada
- Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - Thomas V O Hansen
- Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Genetics Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Malene Djursby
- Department of Clinical Genetics Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Andrew Lee
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Joe Dennis
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - David D Bowtell
- Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- Sir Peter MacCallum, Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
| | - Nadia Traficante
- Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- Sir Peter MacCallum, Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
| | - Orland Diez
- Oncogenetics Group, Vall dHebron Institute of Oncology, Barcelona, Spain
- Clinical and Molecular Genetics Area, University Hospital Vall dHebron, Barcelona, Spain
| | - Judith Balmaña
- Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
- Department of Medical Oncology, University Hospital of Vall d’Hebron, Barcelona, Spain
| | - Stephen B Gruber
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | | | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K Kjær
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Gynaecology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
| | - Estrid Høgdall
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Laurent Castéra
- Department of Cancer Biology and Genetics, Normandy Centre for Genomic and Personalized Medicine, François Baclesse Center, Inserm U1245, Caen, France
| | - Judy Garber
- Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Ramunas Janavicius
- Department of Molecular and Regenerative Medicine, Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
- State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
| | - Ana Osorio
- Centro de Investigación en Red de Enfermedades Raras, Madrid, Spain
- Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain
| | - Lisa Golmard
- Institut Curie, Paris Sciences Lettres Research University, Service de Génétique, Paris, France
| | - Ana Vega
- Centro de Investigación en Red de Enfermedades Raras, Madrid, Spain
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - Fergus J Couch
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Mark Robson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, New York, NY, USA
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Susan M Domchek
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Julie O Culver
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Miguel de la Hoya
- Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain
| | - Douglas F Easton
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - William D Foulkes
- Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, University of Cologne, Cologne, Germany
- Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Marc Tischkowitz
- Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, University of Cologne, Cologne, Germany
- National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - Alfons Meindl
- Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Munich, Germany
| | - Rita K Schmutzler
- Faculty of Medicine and University Hospital Cologne, Center for Familial Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology, University of Cologne, Cologne, Germany
- Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
| | - Paul D P Pharoah
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| | - Antonis C Antoniou
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
| |
Collapse
|
44
|
Jensen A. SP-0505: Particle therapy for salivary gland tumors. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00527-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, Spain L, Azad A, Kwan E, Muthusamy A, Torres J, Parente P, Francis P, Parnis F, Goh J, Gibbs P, Tran B, Anton A. 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
46
|
Christensen SC, Krogh BO, Jensen A, Andersen CBF, Christensen S, Nielsen MS. Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain. Sci Rep 2020; 10:14582. [PMID: 32884039 PMCID: PMC7471916 DOI: 10.1038/s41598-020-71286-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 08/05/2020] [Indexed: 11/17/2022] Open
Abstract
The brain uptake of biotherapeutics for brain diseases is hindered by the blood–brain barrier (BBB). The BBB selectively regulates the transport of large molecules into the brain and thereby maintains brain homeostasis. Receptor-mediated transcytosis (RMT) is one mechanism to deliver essential proteins into the brain parenchyma. Receptors expressed in the brain endothelial cells have been explored to ferry therapeutic antibodies across the BBB in bifunctional antibody formats. In this study, we generated and characterized monoclonal antibodies (mAbs) binding to the basigin receptor, which recently has been proposed as a target for RMT across the BBB. Antibody binding properties such as affinity have been demonstrated to be important factors for transcytosis capability and efficiency. Nevertheless, studies of basigin mAb properties' effect on RMT are limited. Here we characterize different basigin mAbs for their ability to associate with and subsequently internalize human brain endothelial cells. The mAbs were profiled to determine whether receptor binding epitope and affinity affected receptor-mediated uptake efficiency. By competitive epitope binning studies, basigin mAbs were categorized into five epitope bins. mAbs from three of the epitope bins demonstrated properties required for RMT candidates judged by binding characteristics and their superior level of internalization in human brain endothelial cells.
Collapse
Affiliation(s)
- Sarah Christine Christensen
- Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, Building 1116, 8000, Aarhus C, Denmark.,Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Berit Olsen Krogh
- Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Allan Jensen
- Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | | | - Søren Christensen
- Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark
| | - Morten Schallburg Nielsen
- Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, Building 1116, 8000, Aarhus C, Denmark.
| |
Collapse
|
47
|
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol 2020; 158:702-709. [PMID: 32641237 PMCID: PMC7487048 DOI: 10.1016/j.ygyno.2020.06.481] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 06/07/2020] [Indexed: 02/07/2023]
Abstract
PURPOSE Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. METHODS Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery. RESULTS Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival. CONCLUSIONS Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.
Collapse
Affiliation(s)
- Katharine K Brieger
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Siri Peterson
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Alice W Lee
- Department of Public Health, California State University Fullerton, Fullerton, CA, USA
| | - Bhramar Mukherjee
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Kelly M Bakulski
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Aliya Alimujiang
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Hoda Anton-Culver
- Department of Medicine, University of California Irvine, Irvine, CA, USA
| | - Michael S Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - Elisa V Bandera
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Andrew Berchuck
- Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA
| | - David D L Bowtell
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Kathleen R Cho
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Daniel W Cramer
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Anna DeFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia
| | - Jennifer A Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Renée T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dale W Garsed
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
| | | | - Aleksandra Gentry-Maharaj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - Ellen L Goode
- Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Estrid Høgdall
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - David G Huntsman
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada
| | - Hui Shen
- Van Andel Research Institute (VARI), Grand Rapids, MI, USA
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Sharon E Johnatty
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Susan J Jordan
- University of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Jolanta Kupryjanczyk
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Diether Lambrechts
- Vesalius Research Center, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium
| | - Karen McLean
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Usha Menon
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - Francesmary Modugno
- Womens Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, USA
| | - Kirsten Moysich
- Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Roberta Ness
- School of Public Health, University of Texas Health Science Center at Houston (UTHealth), TX, USA
| | - Susan J Ramus
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Jean Richardson
- Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney. Sydney, New South Wales, Australia
| | - Harvey Risch
- Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
| | - Mary Anne Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Britton Trabert
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Argyrios Ziogas
- Department of Medicine, University of California Irvine, Irvine, CA, USA
| | - Kathryn L Terry
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Gillian E Hanley
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - Paul Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Penelope M Webb
- University of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia
| | - Malcolm C Pike
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Celeste Leigh Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
| |
Collapse
|
48
|
Phung MT, Mukherjee B, Lee AW, Webb PM, Risch HA, Doherty JA, Harris HR, Goodman MT, Ness RB, Modugno F, Jensen A, Kjaer SK, Terry KL, Cramer DW, Ziogas A, Anton-Culver H, Pike MC, Wu AH, Pearce CL. Abstract 3498: Ovarian cancer risk factors multiply to create high risk in pre-menopausal women. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-3498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Ovarian cancer is the eighth-most common cancer among women. Although a number of established risk factors exist for this disease, analyses of these exposures have largely not taken into account potential interactions. We present an interaction analysis of eight ovarian cancer risk factors, followed by the creation of modifiable and non-modifiable risk scores for the disease.
Methods: Data used in this analysis come from nine studies in the Ovarian Cancer Association Consortium (OCAC): one from Australia, one from Europe and seven from the US. Analyses were restricted to pre-menopausal women without first-degree family histories of ovarian cancer, leading to a final study population of 1504 cases and 3515 controls. Five potentially modifiable predictors (oral contraceptive (OC) use duration, body mass index, tubal ligation, hysterectomy and breastfeeding) and three non-modifiable predictors (parity, incomplete pregnancies and history of endometriosis) were considered. A complete analysis of interactions between the eight variables as well as with age, race/ethnicity, education level and study site was conducted. No statistically significant pairwise interactions were found with likelihood ratio statistics, thus suggesting no departure from multiplicativity in the odds ratios. The modifiable and non-modifiable risk scores were calculated as the product of the odds ratios for each group of exposures. Logistic regression was used to model the association between ovarian cancer and the risk scores. Age, race/ethnicity, education level and study site were included in the model.
Results: The associations between the second, third and fourth quartiles of the modifiable risk score compared to the lowest quartile were 1.67 (95% CI 1.35-2.09), 2.18 (95% CI 1.76-2.71) and 3.72 (95% CI 3.04-4.57), respectively. The odds ratios for the non-modifiable risk score were 1.17 (95% CI 0.95-1.44), 1.24 (95% CI 0.99-1.54) and 2.06 (95% CI 1.68-2.53), respectively for the second, third and fourth quartiles compared to the first. Women in the highest quartiles of both the modifiable and non-modifiable risk scores, representing 14.6% of the women, had a 7.67-fold increased risk of ovarian cancer (95% CI 4.68-11.39) compared to women in the lowest quartiles for both risk scores (3.6% of the women).
Conclusions: Pre-menopausal women in the highest risk quartiles have a substantially elevated risk of ovarian cancer based on these eight exposures. Modifiable factors contribute more than non-modifiable factors to ovarian cancer risk among pre-menopausal women with no family history in our study. Women in the highest risk group (fourth quartile of both risk scores) could reduce their risk by intervening on the modifiable exposures; for example, 63% of women in this group had not used oral contraceptives and 93% had not had tubal ligation. However, careful consideration of the risks and benefits of such prevention measures is needed.
Citation Format: Minh Tung Phung, Bhramar Mukherjee, Alice W. Lee, Penelope M. Webb, Harvey A. Risch, Jennifer Anne Doherty, Holly R. Harris, Marc T. Goodman, Roberta B. Ness, Francesmary Modugno, Allan Jensen, Susanne K. Kjaer, Kathryn L. Terry, Daniel W. Cramer, Argyrios Ziogas, Hoda Anton-Culver, Malcolm C. Pike, Anna H. Wu, Celeste Leigh Pearce. Ovarian cancer risk factors multiply to create high risk in pre-menopausal women [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3498.
Collapse
Affiliation(s)
- Minh Tung Phung
- 1Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI
| | - Bhramar Mukherjee
- 2Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI
| | - Alice W. Lee
- 3Department of Public Health, California State University Fullerton, Fullerton, CA
| | - Penelope M. Webb
- 4Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Harvey A. Risch
- 5Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT
| | - Jennifer Anne Doherty
- 6Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Holly R. Harris
- 7Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Marc T. Goodman
- 8Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
| | | | - Francesmary Modugno
- 10Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA
| | - Allan Jensen
- 11Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Susanne K. Kjaer
- 11Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Kathryn L. Terry
- 12Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
| | - Daniel W. Cramer
- 12Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
| | - Argyrios Ziogas
- 13Department of Epidemiology, University of California Irvine, Irvine, CA
| | - Hoda Anton-Culver
- 13Department of Epidemiology, University of California Irvine, Irvine, CA
| | - Malcolm C. Pike
- 14Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Anna H. Wu
- 15Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Celeste Leigh Pearce
- 1Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI
| |
Collapse
|
49
|
Muthukumar A, Khoja L, Webb PM, Risch H, Doherty J, Harris H, Goodman M, Ness R, Modugno F, Kjaer SK, Jensen A, Schildkraut J, Berchuck A, Terry KL, Cramer D, Titus LJ, Anton-Culver H, Ziogas A, Wu AH, Pike MC, Pearce CL, Lee AW. Abstract B32: Are ovarian cancer risk factors different for women with endometriosis? Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.ovca19-b32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endometriosis is a common gynecologic disorder that affects approximately 10% of women of reproductive age. It is also a well-established risk factor for ovarian cancer. Whether hormonal-related and other risk factors for ovarian cancer (e.g., parity, oral contraceptive use) are the same for women with and without endometriosis is currently unknown.
Methods: We pooled questionnaire information from 10 population-based case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Data from 8,172 women with invasive epithelial ovarian cancer and 12,464 controls were included in our analysis. Associations of body mass index (BMI), parity, oral contraceptive use, breastfeeding, menopausal hormone therapy use, first-degree family history of ovarian cancer, tubal ligation, and hysterectomy with risk of ovarian cancer were stratified by history of endometriosis and analyzed using logistic regression. All models were conditioned on age, race/ethnicity, education, and OCAC study site. We fit an endometriosis interaction term for each risk factor to evaluate statistical interactions.
Results: Among women with no history of endometriosis, those who had hysterectomies showed a 12% increased risk of ovarian cancer compared to those with intact uteri (OR=1.12, 95% CI 1.01-1.24); an increased risk was not observed among women with endometriosis (OR=0.74, 95% CI 0.53-1.05; p-interaction=0.009). Use of estrogen-progestin hormone therapy was associated with decreased risk ovarian cancer for women with histories of endometriosis (OR=0.69, 95% CI 0.47-1.02), but not for those without endometriosis (OR=0.96, 95% CI 0.87-1.07; p-interaction=0.02). We did not observe any significant statistical interactions for the other risk factors considered, and no interactions were significant after consideration of multiple comparisons.
Conclusions: The associations of hysterectomy and menopausal estrogen-progestin hormone therapy use with risk of ovarian cancer seemed to differ by endometriosis status, suggesting interactions that may need to be considered in ovarian cancer risk profiling strategies. Future investigations into the biology underlying these interactions would be relevant.
Citation Format: Aruna Muthukumar, Lilah Khoja, Penelope M. Webb, Harvey Risch, Jennifer Doherty, Holly Harris, Marc Goodman, Roberta Ness, Francesmary Modugno, Susanne K. Kjaer, Allan Jensen, Joellen Schildkraut, Andrew Berchuck, Kathryn L. Terry, Daniel Cramer, Linda J. Titus, Hoda Anton-Culver, Argyrios Ziogas, Anna H. Wu, Malcolm C. Pike, Celeste L. Pearce, Alice W. Lee. Are ovarian cancer risk factors different for women with endometriosis? [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B32.
Collapse
Affiliation(s)
| | - Lilah Khoja
- 1University of Michigan School of Public Health, Ann Arbor, MI,
| | - Penelope M. Webb
- 2QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia,
| | | | - Jennifer Doherty
- 4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT,
| | - Holly Harris
- 5Fred Hutchinson Cancer Research Center, Seattle, WA,
| | | | - Roberta Ness
- 7University of Texas School of Public Health, Dallas, TX,
| | | | | | - Allan Jensen
- 9Danish Cancer Society Research Center, Copenhagen, Denmark,
| | | | | | | | | | | | | | | | - Anna H. Wu
- 15University of Southern California, Los Angeles, CA,
| | | | | | - Alice W. Lee
- 17California State University Fullerton, Fullerton, CA
| |
Collapse
|
50
|
Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J, Goodman MT, Thompson PJ, Moysich KB, Ness RB, Kjaer SK, Jensen A, Schildkraut JM, Titus LJ, Cramer DW, Bandera EV, Qin B, Sieh W, McGuire V, Sutphen R, Pearce CL, Wu AH, Pike M, Webb PM, Modugno F, Terry KL. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncol 2020; 6:e200421. [PMID: 32239218 DOI: 10.1001/jamaoncol.2020.0421] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Importance Breastfeeding has been associated with a reduced risk of epithelial ovarian cancer in multiple studies, but others showed no association. Whether risk reduction extends beyond that provided by pregnancy alone or differs by histotype is unclear. Furthermore, the observed associations between duration and timing of breastfeeding with ovarian cancer risk have been inconsistent. Objective To determine the association between breastfeeding (ie, ever/never, duration, timing) and ovarian cancer risk overall and by histotype. Design, Setting, and Participants A pooled analysis of parous women with ovarian cancer and controls from 13 case-control studies participating in the Ovarian Cancer Association Consortium was performed. Odds ratios (ORs) and 95% CIs of the overall association were calculated using multivariable logistic regression and polytomous logistic regression for histotype-specific associations. All data were collected from individual sites from November 1989 to December 2009, and analysis took place from September 2017 to July 2019. Exposures Data on breastfeeding history, including duration per child breastfed, age at first and last breastfeeding, and years since last breastfeeding were collected by questionnaire or interview and was harmonized across studies. Main Outcomes and Measures Diagnosis of epithelial ovarian cancer. Results A total of 9973 women with ovarian cancer (mean [SD] age, 57.4 [11.1] years) and 13 843 controls (mean [SD] age, 56.4 [11.7] years) were included. Breastfeeding was associated with a 24% lower risk of invasive ovarian cancer (odds ratio [OR], 0.76; 95% CI, 0.71-0.80). Independent of parity, ever having breastfed was associated with reduction in risk of all invasive ovarian cancers, particularly high-grade serous and endometrioid cancers. For a single breastfeeding episode, mean breastfeeding duration of 1 to 3 months was associated with 18% lower risk (OR, 0.82; 95% CI, 0.76-0.88), and breastfeeding for 12 or more months was associated with a 34% lower risk (OR, 0.66; 95% CI, 0.58-0.75). More recent breastfeeding was associated with a reduction in risk (OR, 0.56; 95% CI, 0.47-0.66 for <10 years) that persisted for decades (OR, 0.83; 95% CI, 0.77-0.90 for ≥30 years; P for trend = .02). Conclusions and Relevance Breastfeeding is associated with a significant decrease in risk of ovarian cancer overall and for the high-grade serous subtype, the most lethal type of ovarian cancer. The findings suggest that breastfeeding is a potentially modifiable factor that may lower risk of ovarian cancer independent of pregnancy alone.
Collapse
Affiliation(s)
- Ana Babic
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.,Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Naoko Sasamoto
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Bernard A Rosner
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.,Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | | | - Susan J Jordan
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,The University of Queensland School of Public Health, Brisbane, Queensland, Australia
| | - Harvey A Risch
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.,Department of Epidemiology, School of Public Health, University of Washington, Seattle
| | - Mary Anne Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.,Department of Epidemiology, School of Public Health, University of Washington, Seattle
| | - Jennifer A Doherty
- Department of Population Health Science, Huntsman Cancer Institute, University of Utah, Salt Lake City
| | - Renée T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marc T Goodman
- Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California
| | - Pamela J Thompson
- Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Kirsten B Moysich
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York
| | - Roberta B Ness
- School of Public Health, University of Texas Health Science Center at Houston, Houston
| | - Susanne K Kjaer
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.,Rigshospitalet, Department of Gynaecology, University of Copenhagen, Copenhagen, Denmark
| | - Allan Jensen
- Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
| | | | - Linda J Titus
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Daniel W Cramer
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Elisa V Bandera
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick
| | - Bo Qin
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick
| | - Weiva Sieh
- Department of Population Health Science and Policy, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Valerie McGuire
- Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, California
| | - Rebecca Sutphen
- Epidemiology Center, College of Medicine, University of South Florida, Tampa
| | - Celeste L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor
| | - Anna H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles
| | - Malcolm Pike
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Penelope M Webb
- Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Francesmary Modugno
- Women's Cancer Research Center, Magee-Womens Research Institute, Hillman Cancer Center, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Kathryn L Terry
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.,Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| |
Collapse
|